

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
23 September 2004 (23.09.2004)

PCT

(10) International Publication Number  
**WO 2004/080950 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 271/28**,  
233/43, A61P 25/08, A61K 31/167, 31/325

(21) International Application Number:  
PCT/DK2004/000162

(22) International Filing Date: 12 March 2004 (12.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA200300392 14 March 2003 (14.03.2003) DK  
60/454,580 14 March 2003 (14.03.2003) US

(71) Applicant (for all designated States except US): **H. LUNDBECK A/S** [DK/DK]; Ottilievej 9, Valby-Copenhagen 2500 (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GREVE, Daniel, Rodriguez** [DK/DK]; Kornvænget 20, Stenløse 3630 (DK). **ROTTLÄNDER, Mario** [DE/DK]; Svanemosen 10, Greve 2670 (DK). **WATSON, William, Patrick** [GB/DK]; Jyllingevej 81 st, Vanløse 2720 (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED ANILINE DERIVATIVES



(57) Abstract: The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

## Substituted aniline derivatives

### Field of the invention

The present invention relates to novel substituted aniline derivatives being openers of the KCNQ family potassium ion channels. The compounds are useful for the prevention, treatment and inhibition of disorders and diseases being responsive to opening of the KCNQ family potassium ion channels, one such disease is epilepsy.

### Background of the invention

Ion channels are cellular proteins that regulate the flow of ions, including potassium, calcium, chloride and sodium into and out of cells. Such channels are present in all animal and human cells and affect a variety of processes including neuronal transmission, muscle contraction, and cellular secretion.

Humans have over 70 potassium channel subunits (Jentsch *Nature Reviews Neuroscience* **2000**, 1, 21-30) with a great diversity with regard to both structure and function. Neuronal potassium channels, which are found in the brain, are primarily responsible for maintaining a negative resting membrane potential, as well as controlling membrane repolarisation following an action potential.

One subset of potassium channel genes is the KCNQ family. Mutations in four out of five KCNQ genes have been shown to underlie diseases including cardiac arrhythmias, deafness and epilepsy (Jentsch *Nature Reviews Neuroscience* **2000**, 1, 21-30).

The KCNQ4 gene is thought to encode the molecular correlate of potassium channels found in outer hair cells of the cochlea and in Type I hair cells of the vestibular apparatus, in which mutations lead to a form of inherited deafness.

KCNQ1 (KvLQT1) is co-assembled with the product of the KCNE1 (minimal K(+)-channel protein) gene in the heart to form a cardiac-delayed rectifier-like K(+) current. Mutations in this channel can cause one form of inherited long QT syndrome

type 1 (LQT1), as well as being associated with a form of deafness (Robbins *Pharmacol Ther* **2001**, 90, 1-19).

5 The genes KCNQ2 and KCNQ3 were discovered in 1988 and appear to be mutated in an inherited form of epilepsy known as benign familial neonatal convulsions (Rogawski *Trends in Neurosciences* **2000**, 23, 393-398). The proteins encoded by the KCNQ2 and KCNQ3 genes are localised in the pyramidal neurons of the human cortex and hippocampus, regions of the brain associated with seizure generation and propagation (Cooper et al. *Proceedings National Academy of Science U S A* **2000**, 97,  
10 4914-4919).

KCNQ2 and KCNQ3 are two potassium channel subunits that form "M-currents" when expressed in vitro. The M-current is a non-inactivating potassium current found in many neuronal cell types. In each cell type, it is dominant in controlling membrane  
15 excitability by being the only sustained current in the range of action potential initiation (Marrion *Annual Review Physiology* **1997**, 59, 483-504). Modulation of the M-current has dramatic effects on neuronal excitability, for example activation of the current will reduce neuronal excitability. Openers of these KCNQ channels or activators of the M-current, will reduce excessive neuronal activity and may thus be  
20 of use in the treatment, prevention or inhibition of seizures and other diseases and disorders characterised by excessive neuronal activity, such as neuronal hyperexcitability including convulsive disorders, epilepsy and neuropathic pain.

Retigabine (D-23129; N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid  
25 ethyl ester) and analogues thereof are disclosed in EP554543. Retigabine is an anti-convulsive compound with a broad spectrum and potent anticonvulsant properties, both in vitro and in vivo. It is active after oral and intraperitoneal administration in rats and mice in a range of anticonvulsant tests including: electrically induced seizures, seizures induced chemically by pentylenetetrazole, picrotoxin and N-methyl-  
30 D-aspartate (NMDA) and in a genetic animal model, the DBA/2 mouse (Rostock et al. *Epilepsy Research* **1996**, 23, 211-223). In addition, retigabine is active in the amygdala kindling model of complex partial seizures, further indicating that this compound has potential for anti-convulsive therapy. In clinical trials, retigabine has

recently shown effectiveness in reducing the incidence of seizures in epileptic patients (Bialer et al. *Epilepsy Research* **2002**, 51, 31-71).

Retigabine has been shown to activate a K(+) current in neuronal cells and the  
5 pharmacology of this induced current displays concordance with the published  
pharmacology of the M-channel, which recently was correlated to the KCNQ2/3 K(+)  
channel heteromultimer. This suggests that activation of KCNQ2/3 channels may be  
responsible for some of the anticonvulsant activity of this agent (Wickenden et al.  
*Molecular Pharmacology* **2000**, 58, 591-600) – and that other agents working by the  
10 same mechanism may have similar uses.

KCNQ 2 and 3 channels have also been reported to be upregulated in models of  
neuropathic pain (Wickenden et al. *Society for Neuroscience Abstracts* **2002**, 454.7),  
and potassium channel modulators have been hypothesised to be active in both  
15 neuropathic pain and epilepsy (Schroder et al. *Neuropharmacology* **2001**, 40, 888-  
898).

Retigabine has also been shown to be beneficial in animal models of neuropathic pain  
(Blackburn-Munro and Jensen *European Journal of Pharmacology* **2003**, 460, 109-  
20 116), and we thus suggest that openers of KCNQ channels will be of use in treating  
pain disorders including neuropathic pain.

The localisation of KCNQ channel mRNA is reported in brain and other central  
nervous system areas associated with pain (Goldstein et al. *Society for Neuroscience*  
25 *Abstracts* **2003**, 53.8).

In addition to a role in neuropathic pain, the expression of mRNA for KCNQ 2-5 in  
the trigeminal and dorsal root ganglia and in the trigeminal nucleus caudalis implies  
that openers of these channels may also affect the sensory processing of migraine pain  
30 (Goldstein et al. *Society for Neuroscience Abstracts* **2003**, 53.8).

Recent reports demonstrate that mRNA for KCNQ 3 and 5, in addition to that for  
KCNQ2, are expressed in astrocytes and glial cells. Thus KCNQ 2, 3 and 5 channels

may help modulate synaptic activity in the CNS and contribute to the neuroprotective effects of KCNQ channel openers (Noda et al., *Society for Neuroscience Abstracts* **2003**, 53.9).

5 Retigabine and other KCNQ modulators may thus exhibit protection against the neurodegenerative aspects of epilepsy, as retigabine has been shown to prevent limbic neurodegeneration and the expression of markers of apoptosis following kainic acid-induced status epilepticus in the rat (Ebert et al. *Epilepsia* **2002**, 43 Suppl 5, 86-95). This may have relevance for preventing the progression of epilepsy in patients, i.e. be  
10 anti-epileptogenic. Retigabine has also been shown to delay the progression of hippocampal kindling in the rat, a further model of epilepsy development (Tober et al. *European Journal Of Pharmacology* **1996**, 303, 163-169).

Thus we suggest that these properties of retigabine and other KCNQ modulators may  
15 prevent neuronal damage induced by excessive neuronal activation, and may be of use in the treatment of neurodegenerative diseases, and be disease modifying (or antiepileptogenic) in patients with epilepsy.

Given that anticonvulsant compounds such as benzodiazepines and chlormethiazole  
20 are used clinically in the treatment of the ethanol withdrawal syndrome and that other anticonvulsant compounds e.g. gabapentin, are very effective in animal models of this syndrome (Watson et al. *Neuropharmacology* **1997**, 36, 1369-1375), we expect that other anticonvulsant compounds such as KCNQ openers will also be effective in this condition.

25 mRNA for KCNQ 2 and 3 subunits are found in brain regions associated with anxiety and emotional behaviours such as bipolar disorder e.g. hippocampus and amygdala (Saganich et al. *Journal of Neuroscience* **2001**, 21, 4609-4624), and retigabine is reportedly active in some animal models of anxiety-like behaviour (Hartz et al.  
30 *Journal of Psychopharmacology* **2003**, 17 suppl 3, A28,B16), and other clinically used anticonvulsant compounds are used in the treatment of bipolar disorder.

WO 200196540 discloses the use of modulators of the M-current formed by expression of KCNQ2 and KCNQ3 genes for insomnia, while WO 2001092526 discloses that modulators of KCNQ5 can be utilized for the treatment of sleep disorders.

5

WO01/022953 describes the use of retigabine for prophylaxis and treatment of neuropathic pain such as allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.

10 WO02/049628 describes the use of retigabine for the prevention, treatment, inhibition and amelioration of anxiety disorders such as anxiety, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia and specific  
15 phobias.

WO97/15300 describes the use of retigabine for the treatment of neurodegenerative disorders such as Alzheimer's ; Huntington's ; sclerosis such as multiple sclerosis and amyotrophic lateral sclerosis; Creutzfeld-Jakob disease; Parkinson's disease; AIDS-  
20 induced encephalopathy and other infection-related encephalopathies being caused by rubella viruses, herpes viruses, borrelia and by unknown pathogens, trauma-induced neurodegenerations, neuronal hyperexcitation states such as in medicament withdrawal or intoxication, and neurodegenerative disorders of the peripheral nervous system such as polyneuropathies and polyneuritides.

25

Hence, there is a great desire for novel compounds, which are potent openers of the KCNQ family potassium channels.

Also desired are novel compounds with improved properties relative to known  
30 compounds, which are openers of the KCNQ family potassium channels, such as retigabine. Improvement of one or more of the following parameters is desired: half-life, clearance, selectivity, interactions with other medications, bioavailability, potency, formulability, chemical stability, metabolic stability, membrane

permeability, solubility and therapeutic index. The improvement of such parameters may lead to improvements such as:


- an improved dosing regime by reducing the number of required doses a day,
- ease of administration to patients on multiple medications,
- 5 ○ reduced side effects,
- enlarged therapeutic index,
- ⊗ improved tolerability or
- ⊗ improved compliance.

10

### Summary of the invention

One object of the present invention is to provide novel compounds, which are potent openers of the KCNQ family potassium channels.

- 15 The compounds of the invention are substituted aniline derivatives of the general formula I or salts thereof




- 20 wherein **Y**, **U**, **X**, **Z**, **s**, **q**, **R<sup>1</sup>**, **R<sup>1'</sup>**, **R<sup>2</sup>** and **R<sup>3</sup>** are as defined below.

The invention further relates to a pharmaceutical composition comprising one or more compounds of formula I and the use thereof.

25

**Detailed description of the invention**

Accordingly, the present invention relates to substituted aniline derivatives of the general formula I



wherein

**U** is O, S or  $\text{NR}^{2'}$ ;

**s** is 0 or 1;

**X** is CO or  $\text{SO}_2$ ;

**Z** is O, S or  $\text{NR}^4$ , wherein **R**<sup>4</sup> is selected from the group consisting of hydrogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl- $\text{C}_{1-6}$ -alk(en/yn)yl, hydroxy- $\text{C}_{1-6}$ -alk(en/yn)yl and hydroxy- $\text{C}_{3-8}$ -cycloalk(en)yl;

**q** is 0 or 1;

**R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of hydrogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl- $\text{C}_{1-6}$ -alk(en/yn)yl, acyl, hydroxy- $\text{C}_{1-6}$ -alk(en/yn)yl, hydroxy- $\text{C}_{3-8}$ -cycloalk(en)yl, halo- $\text{C}_{1-6}$ -alk(en/yn)yl and halo- $\text{C}_{3-8}$ -cycloalk(en)yl;

**R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,

C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl and cyano; provided that when R<sup>2</sup> is halogen or cyano, then s is 0;


5

when s is 1 and U is NR<sup>2'</sup> then R<sup>2'</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl; or  
10 R<sup>2</sup> and R<sup>2'</sup> together form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;


R<sup>3</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl,  
15 Ar-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;

and


20 Y represents a group of formulae **VI**, **VII**, **VIII**, **IX** or **XXX**:




VI




VII



VIII



IX



XXX

wherein

5

the line represents a bond attaching the group represented by Y to the nitrogen atom;

**W** is O or S;

10 **a** is 0, 1, 2 or 3;

**b** is 0, 1, 2, 3 or 4;

**c** is 0 or 1;

15

**d** is 0, 1, 2 or 3;

e is 0, 1 or 2;

f is 0, 1, 2, 3, 4 or 5;

5 g is 0, 1, 2, 3 or 4;

h is 0, 1, 2 or 3; and

each  $R^5$  is independently selected from the group consisting of a  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl, Ar,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, Ar- $C_{1-6}$ -alk(en/yn)yl, acyl,  $C_{1-6}$ -alk(en/yn)yl, halogen, halo- $C_{1-6}$ -alk(en/yn)yl,  $-CO-NR^6R^{6'}$ , cyano, nitro,  $-NR^7R^{7'}$ ,  $-S-R^8$ ,  $-SO_2R^8$  and  $SO_2OR^8$ , or two substituents together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms;

15

$R^6$  and  $R^{6'}$  are independently selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl and Ar;

20

$R^7$  and  $R^{7'}$  are independently selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, Ar and acyl; and

25

$R^8$  is selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, Ar and  $-NR^9R^{9'}$ ; wherein  $R^9$  and  $R^{9'}$  are independently selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl and  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl; with the provisos that when  $R^5$  is  $SO_2OR^8$  then  $R^8$  is not  $-NR^9R^{9'}$  and when  $R^5$  is  $SO_2R^8$ , then  $R^8$  is not a hydrogen atom; or salts thereof.

30

**Detailed description**

One embodiment of the invention relates to compounds of the general formula **I**, wherein **R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl.

5

In another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl.

10

One embodiment of the invention relates to compounds of the general formula **I**, wherein **R**<sup>1</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl and **R**<sup>1'</sup> is selected from the group consisting of acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl.

15

In yet another embodiment the invention relates to compounds of the general formula **I**, wherein **R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl.

20

In yet another embodiment, the invention relates to compounds of formula **I**, wherein one of **R**<sup>1</sup> and **R**<sup>1'</sup> is a hydrogen atom.

25

In yet another embodiment, the invention relates to compounds of formula **I**, wherein at least one of **R**<sup>1</sup> and **R**<sup>1'</sup> is a hydrogen atom.

In a preferred embodiment, the invention relates to compounds of formula **I**, wherein both **R**<sup>1</sup> and **R**<sup>1'</sup> are hydrogen atoms.

30

In another preferred embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of hydrogen and C<sub>1-6</sub>-alk(en/yn)yl.

- 5 In yet another embodiment, the invention relates to compounds of formula **I**, wherein **s** is 1.

In a preferred embodiment, the invention relates to compounds of formula **I**, wherein **s** is 0.

10

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein **R**<sup>2</sup> is selected from the group consisting of Ar, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl.

15

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein **R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen, cyano, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl and Ar-C<sub>3-8</sub>-cycloalk(en)yl; provided that when **R**<sup>2</sup> is halogen or  
20 cyano, then **s** is 0.

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein **R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen, cyano, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar,  
25 Ar-C<sub>1-6</sub>-alk(en/yn)yl and Ar-C<sub>3-8</sub>-cycloalk(en)yl; provided that when **R**<sup>2</sup> is halogen or cyano, then **s** is 0.

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein **R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen,  
30 C<sub>1-6</sub>-alk(en/yn)yl and Ar; provided that when **R**<sup>2</sup> is halogen, then **s** is 0.

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein *s* is 0 and **R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>-alk(en/yn)yl and Ar.

- 5 In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>2</sup> is Ar, typically phenyl substituted with halogen or -N(C<sub>1-6</sub>-alk(en/yn)yl)<sub>2</sub>.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>2</sup> is C<sub>1-6</sub>-alk(en/yn)yl, typically C<sub>1-3</sub>-alk(en/yn)yl.

10

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>2</sup> is C<sub>3-8</sub>-cycloalk(en)yl, typically C<sub>3-6</sub>-cycloalk(en)yl.

- 15 In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>2</sup> is C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, typically C<sub>3-6</sub>-cycloalk(en)yl-C<sub>1-3</sub>-alk(en/yn)yl.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>2</sup> is Ar-C<sub>1-6</sub>-alk(en/yn)yl, typically Ar-C<sub>1-3</sub>-alk(en/yn)yl.

20

In a preferred embodiment, the invention relates to compounds of the general formula **I**, wherein **R**<sup>2</sup> is Ar-C<sub>3-8</sub>-cycloalk(en)yl, typically Ar-C<sub>3-6</sub>-cycloalk(en)yl.

- 25 In yet another embodiment, the invention relates to compounds of formula **I**, wherein *s* is 0 and **R**<sup>2</sup> is different from a hydrogen atom, a halogen atom and C<sub>1-6</sub>-alkyl.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>2</sup> is a hydrogen atom.

- 30 In yet another embodiment, the invention relates to compounds of formula **I**, wherein *s* is 0 and **R**<sup>2</sup> is a hydrogen atom.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 0 and  $R^2$  is different from a hydrogen atom.

5 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 1,  $U$  is O and  $R^2$  is different from a hydrogen atom,  $C_{1-6}$ -alkyl and acyl.

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein  $s$  is 1,  $U$  is S or  $NR^{2'}$  and  $R^2$  is a hydrogen atom.

10 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 0 and  $R^2$  is cyano.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 0 and  $R^2$  is a halogen atom such as a fluoro atom or a chloro atom.

15

In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 1 and  $U$  is O or S.

20 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 1 and  $U$  is  $NR^{2'}$ .

In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 1 and  $U$  is not  $NR^{2'}$ .

25 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 1,  $U$  is  $NR^{2'}$  and  $R^2$  and  $R^{2'}$  are independently selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl and Ar.

30 In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein  $s$  is 1,  $U$  is  $NR^{2'}$  and  $R^{2'}$  is selected from the group consisting of Ar, acyl, hydroxy- $C_{1-6}$ -alk(en/yn)yl, hydroxy- $C_{3-8}$ -cycloalk(en)yl, halo- $C_{1-6}$ -alk(en/yn)yl and halo- $C_{3-8}$ -cycloalk(en)yl.

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein  $s$  is 1,  $U$  is  $NR^{2'}$  and  $R^{2'}$  is selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, Ar- $C_{1-6}$ -alk(en/yn)yl and Ar- $C_{3-8}$ -cycloalk(en)yl.

5

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein  $s$  is 1,  $U$  is  $NR^{2'}$  and  $R^2$  and  $R^{2'}$  together form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom.

- 10 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $R^2$  and  $R^{2'}$  together form pyrrolidin, piperidin, piperazin, morpholin, pyrrol, oxazolidin, thiazolidin or imidazolidin.

- In a preferred embodiment, the invention relates to compounds of formula **I**, wherein  
15  $s$  is 1,  $U$  is  $NR^{2'}$  and none of  $R^2$  and  $R^{2'}$  is a hydrogen atom.

In a preferred embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 1,  $U$  is  $NR^{2'}$  and at least one of  $R^2$  and  $R^{2'}$  is a hydrogen atom.

- 20 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 1,  $U$  is  $NR^{2'}$  and  $R^{2'}$  is a hydrogen atom.

In a preferred embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 1,  $U$  is  $NR^{2'}$  and both  $R^2$  and  $R^{2'}$  are hydrogen atoms.

25

In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $s$  is 1,  $U$  is  $NR^{2'}$  and at least one of  $R^2$  and  $R^{2'}$  is different from Ar, Ar- $C_{1-6}$ -alk(en/yn)yl and Ar- $C_{3-8}$ -cycloalk(en)yl.

- 30 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $X$  is  $SO_2$ .

In a preferred embodiment, the invention relates to compounds of formula **I**, wherein  $X$  is CO.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **q** is 0.

5 In a preferred embodiment, the invention relates to compounds of formula **I**, wherein **q** is 1.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **Z** is S or NR<sup>4</sup>.

10 In a preferred embodiment, the invention relates to compounds of formula **I**, wherein **Z** is O.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>3</sup> is selected from the group consisting of Ar, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl,  
15 hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>3</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl and  
20 Ar-C<sub>3-8</sub>-cycloalk(en)yl.

One embodiment of the invention relates to compounds of the general formula **I**, wherein **R**<sup>3</sup> is Ar; with the proviso that Ar is different from optionally substituted phenyl, optionally substituted condensed phenyl such as naphthyl and optionally  
25 substituted thienyl.

One embodiment of the invention relates to compounds of the general formula **I**, wherein **R**<sup>3</sup> is Ar-C<sub>1-6</sub>-alk(en/yn)yl; with the proviso that Ar-C<sub>1-6</sub>-alk(en/yn)yl is different from optionally substituted phenyl-C<sub>1-6</sub>-alk(en/yn)yl and optionally  
30 substituted condensed phenyl-C<sub>1-6</sub>-alk(en/yn)yl, such as optionally substituted naphthyl-C<sub>1-6</sub>-alk(en/yn)yl.

Another embodiment of the invention relates to compounds of the general formula **I**, wherein **R**<sup>3</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein **Y** is different from optionally substituted thienyl or phenyl when **R**<sup>3</sup> is Ar-C<sub>1-6</sub>-alkyl, wherein Ar is optionally substituted naphtyl and C<sub>1-6</sub>-alk(en/yn)yl is vinylene, 1-propenylene, methylene or ethylene.

In yet another embodiment, the invention relates to compounds of the general formula **I**, wherein **Y** is optionally substituted thienyl or phenyl when **R**<sup>3</sup> is different from Ar-C<sub>1-6</sub>-alkyl, wherein Ar is optionally substituted naphtyl and C<sub>1-6</sub>-alkyl is vinylene, 1-propenylene, methylene or ethylene.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **X** is CO, **q** is 0 and **R**<sup>3</sup> is different from C<sub>1-4</sub>-alkyl, acyl and phenyl optionally being substituted by hydroxyl or C<sub>1-4</sub>-alkanyloxy.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **X** is CO, **q** is 0 and **R**<sup>3</sup> is C<sub>1-6</sub>-alk(en/yn)yl, with the proviso that **R**<sup>3</sup> is different from a methyl group.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>3</sup> is C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl or C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl.

In a preferred embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>3</sup> is C<sub>1-6</sub>-alk(en/yn)yl.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **R**<sup>3</sup> is not a CH<sub>3</sub>-group.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $R^3$  is a  $CH_3$ -group.

5 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $R^3$  is ethyl.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $R^3$  is isopropyl.

10 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $R^3$  is isopropylmethyl.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $R^3$  is *tert*-butylmethyl.

15 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $R^3$  is Ar- $C_{1-6}$ -alk(en/yn)yl.

20 In yet another embodiment, the invention relates to compounds of formula **I**, wherein  $R^3$  is Ar-methyl.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein **Y** represents a group of formulae **IX** or **XXX**.

25 In yet another embodiment, the invention relates to compounds of formula **I**, wherein each  $R^5$  is independently selected from the group consisting of Ar- $C_{1-6}$ -alk(en/yn)yl, acyl,  $-CO-NR^6R^{6'}$ , cyano, nitro,  $-NR^7R^{7'}$ ,  $-S-R^8$ ,  $-SO_2R^8$  and  $SO_2OR^8$ .

30 In yet another embodiment, the invention relates to compounds of formula **I**, wherein each  $R^5$  is independently selected from the group consisting of  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, Ar, halogen,

halo-C<sub>1-6</sub>-alk(en/yn)yl and C<sub>1-6</sub>-alk(an/en/yn)yl; or two R<sup>5</sup> together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms.

5 In a preferred embodiment, the invention relates to compounds of formula I, wherein each R<sup>5</sup> is independently selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl and C<sub>1-6</sub>-alk(an/en/yn)yl; or two R<sup>5</sup> together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms.

10 In another preferred embodiment, the invention relates to compounds of formula I, wherein each R<sup>5</sup> is independently selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, halogen, cyano, halo-C<sub>1-6</sub>-alk(en/yn)yl and C<sub>1-6</sub>-alk(an/en/yn)yl; or two adjacent substituents together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms.

15

In yet another embodiment, the invention relates to compounds of formula I, wherein each R<sup>5</sup> is independently selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl and C<sub>1-6</sub>-alk(an/en/yn)yl.

20 In yet another embodiment, the invention relates to compounds of formula I, wherein each R<sup>5</sup> is independently selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, halogen, cyano, halo-C<sub>1-6</sub>-alk(en/yn)yl and C<sub>1-6</sub>-alk(an/en/yn)yl.

25 In yet another embodiment, the invention relates to compounds of formula I, wherein two adjacent R<sup>5</sup> together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms.

In yet another embodiment, the invention relates to compounds of formula I, wherein  
30 two adjacent R<sup>5</sup> together form a 5-8 membered saturated or unsaturated carbocyclic ring.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein two adjacent  $R^5$  together form

- 5  $-(CH_2)_{n^*}-CH_2-$ ,  $-CH=CH-(CH_2)_{m^*}-$ ,  $-CH_2-CH=CH-(CH_2)_{p^*}-$ ,  
 $-(CH_2)_{n^*}-O-$ ,  $-O-(CH_2)_{m^*}-O-$ ,  $-CH_2-O-(CH_2)_{p^*}-O-$ ,  $-CH_2-O-CH_2-O-CH_2-$ ,  
 $-(CH_2)_{n^*}-S-$ ,  $-S-(CH_2)_{m^*}-S-$ ,  $-CH_2-S-(CH_2)_{p^*}-S-$ ,  $-CH_2-S-CH_2-S-CH_2-$ ,  
 $-(CH_2)_{n^*}-NH-$ ,  $-NH-(CH_2)_{m^*}-NH-$ ,  $-CH_2-NH-(CH_2)_{p^*}-NH-$ ,  $-CH=CH-NH-$ ,  
 $-O-(CH_2)_{m^*}-NH-$ ,  $-CH_2-O-(CH_2)_{p^*}-NH-$  or  $-O-(CH_2)_{p^*}-NH-CH_2-$ ,  $-S-(CH_2)_{m^*}-NH-$ ,  
 $-N=CH-NH-$ ,  $-N=CH-O-$  or  $-N=CH-S-$ , wherein  $m^*$  is 1, 2 or 3,  $n^*$  is 2, 3 or 4 and  $p^*$  is 1 or 2.

10

In yet another embodiment, the invention relates to compounds of formula **I**, wherein two adjacent  $R^5$  together form  $-(CH_2)_{n^*}-CH_2-$ ,  $-CH=CH-(CH_2)_{m^*}-$ ,  $-CH_2-CH=CH-(CH_2)_{p^*}-$ , wherein  $m^*$  is 1, 2 or 3,  $n^*$  is 2, 3 or 4 and  $p^*$  is 1 or 2.

- 15 In yet another embodiment, the invention relates to compounds of formula **I**, wherein two adjacent  $R^5$  together form  $-(CH_2)_{n^*}-CH_2-$  wherein  $n^*$  is 2, 3 or 4.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein two adjacent  $R^5$  together form  $-(CH_2)_3-$ .

20

In yet another embodiment, the invention relates to compounds of formula **I**, wherein one  $R^5$  is a halogen atom, typically a fluoro or chloro atom.

- 25 In yet another embodiment, the invention relates to compounds of formula **I**, wherein two substituents  $R^5$  are independently selected halogen atoms. Such halogen atoms are typically selected from the group consisting of fluoro and chloro atoms.

In yet another embodiment, the invention relates to compounds of formula **I**, wherein one  $R^5$  is cyano.

30

In yet another embodiment, the invention relates to compounds of formula **I**, wherein one  $R^5$  is  $C_{1-6}$ -alk(en/yn)yl.

In yet another embodiment, the invention relates to compounds of formula I, wherein one  $R^5$  is halo- $C_{1-6}$ -alk(en/yn)yl, typically trifluoromethyl.

5 In yet another embodiment, the invention relates to compounds of formula I, wherein one  $R^5$  is  $C_{3-8}$ -cycloalk(en)yl.

In yet another embodiment, the invention relates to compounds of formula I, wherein one  $R^5$  is Ar, typically phenyl.

10 In yet another embodiment, the invention relates to compounds of formula I, wherein one  $R^5$  is  $C_{1-6}$ -alk(en/yn)oxy.

In yet another embodiment, the invention relates to compounds of formula I, wherein two adjacent  $R^5$  form a 5-8 membered saturated carbocyclic ring.

15

In yet another embodiment, the invention relates to compounds of formula I, with the proviso that when X is CO, q is 0 and  $R^3$  is  $C_{1-6}$ -alk(en/yn)yl such as a methyl group then s is not 0 when  $R^2$  is a hydrogen atom.

20 In yet another embodiment, the invention relates to compounds of formula I, with the proviso that when X is CO, q is 0 and  $R^3$  is  $C_{1-6}$ -alk(en/yn)yl such as a methyl group, then  $R^2$  is different from a hydrogen atom when s is 1.

In yet another embodiment, the invention relates to compounds of formula I, with the proviso that when s is 0 and  $R^2$  is a hydrogen atom then  $NH-X-(Z)_q-R^3$  is not  
25 acetamide.

In yet another embodiment, the compound of formula I is not:

N-[4-[(4-aminophenyl)amino]methyl]phenyl]-acetamide;

N-[4-[(4-amino-2-methylphenyl)amino]methyl]phenyl]-acetamide;

30 N-[4-[(4-amino-3-methylphenyl)amino]methyl]phenyl]-acetamide;

2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)-benzamide;

N-[4-[(3,4,5-trimethoxyphenyl)amino]methyl]phenyl]-acetamide;

N-[4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]methyl]phenyl]-acetamide;

N-[4-[[[3-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[[2-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]-acetamide;

5 N-[4-[[[4-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[[(4-amino-3,5-dichlorophenyl)amino]methyl]phenyl]- acetamide;

N-[4-[[[(2,4-diamino-6-quinazoliny]amino]methyl]phenyl]- acetamide; or

N-[4-[[[(2,4-diamino-6-quinazoliny]amino]methyl]phenyl]- acetamide.

10 In yet another embodiment, the compound of formula I is not:

2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridiny]-benzamide;

N-[4-[[[(3,4,5-trimethoxyphenyl)amino]methyl]phenyl]-acetamide;

N-[4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]methyl]phenyl]-

15 acetamide;

N-[4-[[[3-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[[2-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]-acetamide;

N-[4-[[[4-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[[(4-amino-3,5-dichlorophenyl)amino]methyl]phenyl]- acetamide;


20 N-[4-[[[(2,4-diamino-6-quinazoliny]amino]methyl]phenyl]- acetamide; or

N-[4-[[[(2,4-diamino-6-quinazoliny]amino]methyl]phenyl]- acetamide.

The molecular weight of the compounds of the invention may vary from compound to compound. The molecular weight of a compound of formula I is typically more than

25 200 and less than 600, and more typically more than 250 and less than 550.

One aspect of the invention, relates to compounds of general formula **XI** and salts thereof:



wherein  $f$ ,  $s$ ,  $q$ ,  $U$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^3$  and  $R^5$  are as defined above, accordingly any  
of  $f$ ,  $s$ ,  $q$ ,  $U$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^{2'}$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^{6'}$ ,  $R^7$ ,  $R^{7'}$ ,  $R^8$ ,  $R^9$  and  $R^{9'}$  are as  
5 defined under formula I. Any of the embodiments related to formula I are also  
embodiments of formula **XI**.

In one embodiment, the invention relates to compounds of the general formula **XI**,  
which is not substituted by  $R^5$ .

10


In another embodiment, the invention relates to compounds of the general formula **XI**  
being monosubstituted by  $R^5$ , such as in the ortho-, meta- or para-position.

In yet another embodiment, the invention relates to compounds of the general formula  
15 **XI** being disubstituted by  $R^5$ , such as in the ortho- and para-position, in the meta- and  
para-position and in the ortho- and meta-position.

In yet another embodiment, the invention relates to compounds of the general formula  
**XI** being trisubstituted by  $R^5$ .

20 Another aspect of the invention relates to compounds of the general formula **XII** or  
salts thereof:

24



wherein **g**, **h**, **s**, **q**, **U**, **X**, **Z**, **R<sup>1</sup>**, **R<sup>1'</sup>**, **R<sup>2</sup>**, **R<sup>3</sup>** and **R<sup>5</sup>** are as defined above, accordingly any of **g**, **h**, **s**, **q**, **U**, **X**, **Z**, **R<sup>1</sup>**, **R<sup>1'</sup>**, **R<sup>2</sup>**, **R<sup>2'</sup>**, **R<sup>3</sup>**, **R<sup>4</sup>**, **R<sup>5</sup>**, **R<sup>6</sup>**, **R<sup>6'</sup>**, **R<sup>7</sup>**, **R<sup>7'</sup>**, **R<sup>8</sup>**, **R<sup>9</sup>** and **R<sup>9'</sup>** are as defined under formula I. Any of the embodiments related to formula I are also

5   embodiments of formula **XII**.

In one embodiment, the invention relates to compounds of the general formula **XII**, wherein the nitrogen atom is attached to position 1 of the naphthyl group.

10   In another embodiment, the invention relates to compounds of the general formula **XII**, wherein the nitrogen atom is attached to position 2 of the naphthyl group.

In yet another embodiment, the invention relates to compounds of the general formula **XII**, wherein **g** is 0, 1, 2 or 3, typically 0, 1 or 2.

15

In yet another embodiment, the invention relates to compounds of the general formula **XII**, wherein **h** is 0, 1 or 2, typically 0 or 1.

In yet another embodiment, the invention relates to compounds of the general formula **XII**, which are not substituted by **R<sup>5</sup>**.

20


In yet another embodiment, the invention relates to compounds of the general formula **XII** being monosubstituted by **R<sup>5</sup>**.

In yet another embodiment, the invention relates to compounds of the general formula **XII** being disubstituted by **R<sup>5</sup>**.

25

In yet another embodiment, the invention relates to compounds of the general formula **XII** being trisubstituted by  $R^5$ .

Yet another aspect of the invention relates to compounds of the general formula **XIII** or salts thereof:



wherein  $a$ ,  $s$ ,  $q$ ,  $U$ ,  $W$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^3$  and  $R^5$  are as defined above, accordingly any of  $a$ ,  $s$ ,  $q$ ,  $U$ ,  $W$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^{2'}$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^{6'}$ ,  $R^7$ ,  $R^{7'}$ ,  $R^8$ ,  $R^9$  and  $R^{9'}$  are as defined under formula I. Any of the embodiments related to formula I are also embodiments of formula **XIII**.

In one embodiment, the invention relates to compounds of the general formula **XIII**, wherein the nitrogen atom is attached to position 2 of the heteroaromatic group.

In another embodiment, the invention relates to compounds of the general formula **XIII**, wherein the nitrogen atom is attached to position 3 of the heteroaromatic group.


In yet another embodiment, the invention relates to compounds of the general formula **XIII**, wherein  $a$  is 0, 1 or 2.

In yet another embodiment, the invention relates to compounds of the general formula **XIII**, which are not substituted by  $R^5$ .

In yet another embodiment, the invention relates to compounds of the general formula **XIII** being monosubstituted by  $R^5$ .

In yet another embodiment, the invention relates to compounds of the general formula **XIII** being disubstituted by  $R^5$ .

Yet another aspect of the invention relates to compounds of the general formula **XIV** or salts thereof:



wherein  $b$ ,  $c$ ,  $s$ ,  $q$ ,  $U$ ,  $W$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^3$  and  $R^5$  are as defined above, accordingly any of  $b$ ,  $c$ ,  $s$ ,  $q$ ,  $U$ ,  $W$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^{2'}$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^{6'}$ ,  $R^7$ ,  $R^{7'}$ ,  $R^8$ ,  $R^9$  and  $R^{9'}$  are as defined under formula I. Any of the embodiments related to formula I are also embodiments of formula **XIV**.

In one embodiment, the invention relates to compounds of the general formula **XIV**, wherein the nitrogen atom is attached to position 2 of the heteroaromatic group.

In another embodiment, the invention relates to compounds of the general formula **XIV**, wherein the nitrogen atom is attached to position 3 of the heteroaromatic group.

In yet another embodiment, the invention relates to compounds of the general formula **XIV**, wherein  $b$  is 0, 1, 2 or 3, typically 0, 1 or 2.

In yet another embodiment, the invention relates to compounds of the general formula **XIV**, wherein  $c$  is 0 or 1, typically 0.


In yet another embodiment, the invention relates to compounds of the general formula **XIV**, which is not substituted by  $R^5$ .

In yet another embodiment, the invention relates to compounds of the general formula **XIV** being monosubstituted by  $R^5$ .

In yet another embodiment, the invention relates to compounds of the general formula **XIV** being disubstituted by  $R^5$ .

In yet another embodiment, the invention relates to compounds of the general formula **XIV** being trisubstituted by  $R^5$ .

Yet another aspect of the invention relates to compounds of the general formula **XV** or salts thereof:



wherein  $d$ ,  $e$ ,  $s$ ,  $q$ ,  $U$ ,  $W$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^3$  and  $R^5$  are as defined above, accordingly  $d$ ,  $e$ ,  $s$ ,  $q$ ,  $U$ ,  $W$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^{2'}$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^6'$ ,  $R^7$ ,  $R^7'$ ,  $R^8$ ,  $R^9$  and  $R^{9'}$  are as defined under formula **I**. Any of the embodiments related to formula **I** are also embodiments of formula **XV**.

In one embodiment, the invention relates to compounds of the general formula **XV**, wherein the nitrogen atom is attached to position 4 of the heteroaromatic group.

20

In another embodiment, the invention relates to compounds of the general formula **XV**, wherein the nitrogen atom is attached to position 5 of the heteroaromatic group.

In one embodiment, the invention relates to compounds of the general formula **XV**, wherein the nitrogen atom is attached to position 6 of the heteroaromatic group.

25

In another embodiment, the invention relates to compounds of the general formula **XV**, wherein the nitrogen atom is attached to position 7 of the heteroaromatic group.

5 In yet another embodiment, the invention relates to compounds of the general formula **XV**, wherein **d** is 0, 1 or 2, typically 0 or 1.

In yet another embodiment, the invention relates to compounds of the general formula **XV**, wherein **e** is 0 or 1.

10 In yet another embodiment, the invention relates to compounds of the general formula **XV**, which is not substituted by **R<sup>5</sup>**.

In yet another embodiment, the invention relates to compounds of the general formula **XV** being monosubstituted by **R<sup>5</sup>**.

15

In yet another embodiment, the invention relates to compounds of the general formula **XV** being disubstituted by **R<sup>5</sup>**.

20 In yet another embodiment, the invention relates to compounds of the general formula **XV** being trisubstituted by **R<sup>5</sup>**.

The compounds of the following list and salts thereof are preferred:

- {2-Amino-4-[(4-tert-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*(2-Amino-4-phenylaminomethyl-phenyl)-carbamic acid ethyl ester;*  
25 *[2-Amino-4-(naphthalen-2-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;*  
*[2-Amino-4-(p-tolylamino-methyl)-phenyl]-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-trifluoromethylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-chlorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
30 *{2-Amino-4-[(3-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(2-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*[2-Amino-4-(biphenyl-4-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;*

- {2-Amino-4-[(2,4-difluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-methoxyphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-cyclohexylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*[2-Amino-4-(indan-5-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;*  
5 *{2-Amino-4-[(4-isopropylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*and*  
*{2-Amino-4-[(4-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester.*

- In another embodiment, the compounds of the following list and salts thereof are  
10 preferred:
- {2-Amino-4-[(4-tert-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*(2-Amino-4-phenylaminomethyl-phenyl)-carbamic acid ethyl ester;*  
*[2-Amino-4-(naphthalen-2-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;*  
*[2-Amino-4-(p-tolylamino-methyl)-phenyl]-carbamic acid ethyl ester;*  
15 *{2-Amino-4-[(4-trifluoromethylphenylamino)-methyl]-phenyl}-carbamic acid ethyl*  
*ester;*  
*{2-Amino-4-[(4-chlorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(3-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
20 *{2-Amino-4-[(2-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*[2-Amino-4-(biphenyl-4-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;*  
*{2-Amino-4-[(2,4-difluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-methoxyphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-cyclohexylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
25 *[2-Amino-4-(indan-5-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-isopropylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}carbamic acid ethyl*  
*ester;*  
30 *{2-Amino-4-[(2,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(2,3-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(3,5-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(3,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*

- {2-Amino-4-[(3-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*
- {2-Amino-4-[(3-fluoro-4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*
- 5 *{2-Amino-4-[(3,4-difluorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-cyanophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-fluoro-3-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(3-chloro-4-methylphenylamino)methyl]phenyl}carbamic acid ethyl*
- 10 *ester;*  
*{2-Amino-4-[(3-chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*[2-Amino-4-(m-tolylaminomethyl)phenyl]carbamic acid ethyl ester;*  
*{2-Amino-4-[1-(4-chlorophenylamino)ethyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[1-(4-trifluoromethylphenylamino)ethyl]phenyl}carbamic acid ethyl*
- 15 *ester;*  
*N-{2-Amino-4-[(3-fluorophenylamino)methyl]phenyl}-2,2-dimethylpropionamide;*  
*{4-[(4-Chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{4-[(4-Trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{4-[1-(4-Chlorophenylamino)ethyl]phenyl}carbamic acid ethyl ester;*
- 20 *{4-[(4-Fluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester;*  
*{4-[(4-Chlorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester;*  
*{2-Methyl-4-[(4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{4-[(3,4-Difluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester;*
- 25 *{4-[(3-Fluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester;*  
*{2-Chloro-4-[(4-chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Chloro-4-[(4-trifluoromethylphenylamino)-methyl]phenyl}-carbamic acid ethyl ester;*  
*{2-Chloro-4-[(4-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*
- 30 *{2-Chloro-4-[(3-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*

- {4-[(4-Chlorophenylamino)methyl]-2-fluorophenyl}carbamic acid ethyl ester;  
 {4-[(4-Chloro-3-fluorophenylamino)methyl]-2-fluorophenyl}carbamic acid ethyl  
 ester;  
 {2-Fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl  
 5 ester;  
 {4'-Dimethylamino-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl}carbamic acid  
 ethyl ester;  
 {4'-Dimethylamino-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl}carbamic  
 acid ethyl ester;  
 10 {4'-Chloro-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl}carbamic acid ethyl ester;  
 {4'-Chloro-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl}carbamic acid  
 ethyl ester;  
 N-{4-[(4-chlorophenylamino)methyl]phenyl}butyramide;  
 N-{4-[(3,4-dichlorophenylamino)methyl]phenyl}butyramide;  
 15 N-{4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}butyramide;  
 N-{4[(4-fluoro-phenylamino)methyl]-2-methylphenyl}butyramide;  
 N-{4[(3-fluorophenylamino)methyl]-2-methylphenyl}butyramide;  
 N-{4-[(4-chlorophenylamino)methyl]-2-methylphenyl}butyramide;  
 N-{4-[(3,4-dichlorophenylamino)methyl]-2-methylphenyl}butyramide;  
 20 N-{4-[(4-chloro-3-fluorophenylamino)methyl]-2-methylphenyl}butyramide;  
 N-{2-chloro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide;  
 N-{2-chloro-4-[(4-fluorophenylamino)methyl]phenyl}butyramide;  
 N-{2-chloro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide;  
 N-{2-chloro-4-[(4-chlorophenylamino)methyl]phenyl}butyramide;  
 25 N-{2-chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl}butyramide;  
 N-{2-chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}butyramide;  
 N-{2-fluoro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide;  
 N-{4-[(4-chlorophenylamino)methyl]-2-fluorophenyl}butyramide;  
 N-{2-fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide;  
 30 N-{4-[(3,4-dichlorophenylamino)methyl]-2-fluorophenyl}butyramide; and  
 N-{4-[(4-chloro-3-fluorophenylamino)methyl]-2-fluorophenyl}butyramide.

- According to one embodiment, the invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or diluents and a compound of formula I wherein Y, U, X, Z, s, q, R<sup>1</sup>, R<sup>1'</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined above, accordingly any of s, q, U, X, Z, Y, W, R<sup>4</sup>, R<sup>1</sup>, R<sup>1'</sup>, R<sup>2</sup>, R<sup>2'</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>6'</sup>, R<sup>7</sup>, R<sup>7'</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>9'</sup> are as defined under formula I, or salts thereof.
- Pharmaceutical compositions of the invention may thus comprise one or more compounds of formula I or salts thereof, such as one compound of formula I or a salt thereof; or two compounds of formula I or salts thereof; or three compounds of formula I or salts thereof.
- 10 According to another embodiment, the invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or diluents and a compound of formula XI wherein f, s, q, U, X, Z, R<sup>1</sup>, R<sup>1'</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are as defined above, accordingly any of f, s, q, U, X, Z, R<sup>1</sup>, R<sup>1'</sup>, R<sup>2</sup>, R<sup>2'</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>6'</sup>, R<sup>7</sup>, R<sup>7'</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>9'</sup> are as defined under formula XI, or salts thereof.
- 15 Pharmaceutical compositions of the invention may thus comprise one or more compounds of formula XI or salts thereof, such as one compound of formula XI or a salt thereof; or two compounds of formula XI or salts thereof; or three compounds of formula XI or salts thereof.
- 20 According to yet another embodiment, the invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or diluents and a compound of formula XII wherein g, h, s, q, U, X, Z, R<sup>1</sup>, R<sup>1'</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are as defined above, accordingly any of g, h, s, q, U, X, Z, R<sup>1</sup>, R<sup>1'</sup>, R<sup>2</sup>, R<sup>2'</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>6'</sup>, R<sup>7</sup>, R<sup>7'</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>9'</sup> are as defined under formula XII, or salts thereof.
- 25 Pharmaceutical compositions of the invention may thus comprise one or more compounds of formula XII or salts thereof, such as one compound of formula XII or a salt thereof; or two compounds of formula XII or salts thereof; or three compounds of formula XII or salts thereof.
- 30 According to yet another embodiment, the invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or diluents and a compound of formula XIII wherein a, s, q, U, W, X, Z, R<sup>1</sup>, R<sup>1'</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are as defined above, accordingly any of a, s, q, U, X, Z, W, R<sup>1</sup>, R<sup>1'</sup>, R<sup>2</sup>, R<sup>2'</sup>, R<sup>3</sup>, R<sup>4</sup>,

$R^5$ ,  $R^6$ ,  $R^{6'}$ ,  $R^7$ ,  $R^{7'}$ ,  $R^8$ ,  $R^9$  and  $R^{9'}$  are as defined under formula XIII, or salts thereof.

Pharmaceutical compositions of the invention may thus comprise one or more compounds of formula XIII or salts thereof, such as one compound of formula XIII or a salt thereof; or two compounds of formula XIII or salts thereof; or three compounds of formula XIII or salts thereof.

According to yet another embodiment, the invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or diluents and a compound of formula XIV wherein  $b$ ,  $c$ ,  $s$ ,  $q$ ,  $U$ ,  $W$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^3$  and  $R^5$  are as defined above, accordingly any of  $b$ ,  $c$ ,  $s$ ,  $q$ ,  $U$ ,  $X$ ,  $Z$ ,  $W$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^2'$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^{6'}$ ,  $R^7$ ,  $R^{7'}$ ,  $R^8$ ,  $R^9$  and  $R^{9'}$  are as defined under formula XIV, or salts thereof. Pharmaceutical compositions of the invention may thus comprise one or more compounds of formula XIV or salts thereof, such as one compound of formula XIV or a salt thereof; or two compounds of formula XIV or salts thereof; or three compounds of formula XIV or salts thereof.

According to yet another embodiment, the invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or diluents and a compound of formula XV wherein  $d$ ,  $e$ ,  $s$ ,  $q$ ,  $U$ ,  $W$ ,  $X$ ,  $Z$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^3$  and  $R^5$  are as defined above, accordingly  $d$ ,  $e$ ,  $s$ ,  $q$ ,  $U$ ,  $X$ ,  $Z$ ,  $W$ ,  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^{2'}$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^{6'}$ ,  $R^7$ ,  $R^{7'}$ ,  $R^8$ ,  $R^9$  and  $R^{9'}$  are as defined under formula XV, or salts thereof.

Pharmaceutical compositions of the invention may thus comprise one or more compounds of formula XV or salts thereof, such as one compound of formula XV or a salt thereof; or two compounds of formula XV or salts thereof; or three compounds of formula XV or salts thereof.

The invention provides a pharmaceutical composition for oral or parenteral administration, said pharmaceutical composition comprising at least one compound of formula I or a salt thereof in a therapeutically effective amount together with one or more pharmaceutically acceptable carriers or diluents.

In one aspect, the compounds of the invention may be administered as the only therapeutically effective compound.

- In another aspect the compounds of the invention may be administered as a part of a combination therapy, i.e. the compounds of the invention may be administered in combination with other therapeutically effective compounds having e.g. anti-convulsive properties. The effects of such other compounds having anti-convulsive properties may include but not be limited to activities on:
- ion channels such as sodium, potassium, or calcium channels
  - the excitatory amino acid systems e.g. blockade or modulation of NMDA receptors
  - the inhibitory neurotransmitter systems e.g. enhancement of GABA release, or blockade of GABA-uptake or
  - membrane stabilisation effects.

Current anti-convulsive medications include, but are not limited to, tiagabine, carbamazepine, sodium valproate, lamotrigine, gabapentin, pregabalin, ethosuximide, levetiracetam, phenytoin, topiramate, zonisamide as well as members of the benzodiazepine and barbiturate class.

In one aspect, the compounds of the invention have been found to have effect on potassium channels of the KCNQ family, in particular the KCNQ2 subunit.

- In one embodiment, the invention relates to the use of one or more compounds according to the invention in a method of treatment. The disorder or condition to be prevented, treated or inhibited is responsive to an increased ion flow in a potassium channel such as the KCNQ family potassium ion channels. Such disorder or condition is preferably a disorder or condition of the central nervous system.

The compounds of the invention are considered useful for increasing ion flow in a voltage-dependent potassium channel in a mammal such as a human.

- The compounds of the invention are considered useful for the prevention, treatment or inhibition of a disorder or condition being responsive to an increased ion flow in a potassium channel such as the KCNQ family potassium ion channels. Such disorder or condition is preferably a disorder or condition of the central nervous system.

The compounds of the invention are thus considered useful for preventing, treating or inhibiting disorders or diseases such as seizure disorders, neuropathic and migraine pain disorders, anxiety disorders and neurodegenerative disorders.

- 5 Accordingly, the compounds of the invention are considered useful for the prevention, treatment or inhibition of disorders or conditions such as convulsions, epilepsy, anxiety disorders, neuropathic pain and neurodegenerative disorders.

- 10 According to one particular aspect, the compounds of the invention are considered to be useful for preventing, treating or inhibiting seizure disorders such as convulsions, epilepsy and status epilepticus.

- In one embodiment, the compounds of the invention are considered useful in the prevention, treatment and inhibition of convulsions.

- 15 In another embodiment, the compounds of the invention are considered useful in the prevention, treatment and inhibition of epilepsy, epileptic syndromes and epileptic seizures.

- 20 In yet another embodiment, the compounds of the invention are considered useful in the prevention, treatment and inhibition of anxiety disorders such as anxiety and conditions and diseases related to panic attack, agoraphobia, panic disorder with agoraphobia, panic disorder without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia and other specific phobias, obsessive-  
25 compulsive disorder, posttraumatic stress disorder, acute stress disorders, generalized anxiety disorder, anxiety disorder due to general medical condition, substance-induced anxiety disorder, separation anxiety disorder, adjustment disorders, performance anxiety, hypochondriacal disorders, anxiety disorder due to general medical condition and substance-induced anxiety disorder and anxiety disorder not  
30 otherwise specified.

In yet another embodiment, the compounds of the invention are considered useful in the prevention, treatment and inhibition of neuropathic pain and migraine pain

disorders such as allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.

In yet another embodiment, the compounds of the invention are considered useful in the prevention, treatment and inhibition of neurodegenerative disorders such as Alzheimer's disease; Huntington's chorea; multiple sclerosis; amyotrophic lateral sclerosis; Creutzfeld-Jakob disease; Parkinson's disease; encephalopathies induced by AIDS or infection by rubella viruses, herpes viruses, borrelia and unknown pathogens; trauma-induced neurodegenerations; neuronal hyperexcitation states such as in medicament withdrawal or intoxication; and neurodegenerative diseases of the peripheral nervous system such as polyneuropathies and polyneuritides.

In yet another embodiment, the compounds of the invention are considered useful in the prevention, treatment and inhibition of neurodegenerative disorders such as Alzheimer's disease; Huntington's chorea; multiple sclerosis; amyotrophic lateral sclerosis; Creutzfeld-Jakob disease; Parkinson's disease; encephalopathies induced by AIDS or infection by rubella viruses, herpes viruses, borrelia and unknown pathogens; and trauma-induced neurodegenerations.

In yet another embodiment, the compounds of the invention are considered useful in the prevention, treatment and inhibition of neuronal hyperexcitation states such as in medicament withdrawal or intoxication.

The invention provides compounds showing effect in one or more of the following tests:

- 25     • “Relative efflux through the KCNQ2 channel”  
Which is a measure of the potency of the compound at the target channel
- “Maximum electroshock”  
Which is a measure of seizures induced by non-specific CNS stimulation by electrical means
- 30     ○ “Pilocarpine induced seizures”  
Seizures induced by pilocarpine are often difficult to treat with many existing antiseizure medications and so reflect a model of “drug resistant seizures”
- “Electrical seizure-threshold tests” and “Chemical seizure-threshold tests”

These models measure the threshold at which seizures are initiated, thus being models that detect whether compounds could delay seizure initiation.

• “Amygdala kindling”

5 Which is used as a measure of disease progression, as in normal animals the seizures in this model get more severe as the animal receives further stimulations.

According to one particular aspect of the invention, the compounds are KCNQ2 active with an  $EC_{50}$  of less than 15000nM such as less than 10000nM as measured by the  
10 test “Relative efflux through the KCNQ2 channel” which is described below.

According to one particular aspect of the invention, the compounds are KCNQ2 active with an  $EC_{50}$  of less than 2000nM such as less than 1500nM as measured by the test “Relative efflux through the KCNQ2 channel” which is described below.

15 According to another particular aspect of the invention, the compounds are KCNQ2 active with an  $EC_{50}$  of less than 200nM such as less than 150nM as measured by the test “Relative efflux through the KCNQ2 channel” which is described below.

According to another particular aspect of the invention, the compounds have an  $ED_{50}$   
20 of less than 15 mg/kg in the test “Maximum electroshock” which is described below.

According to yet another particular aspect of the invention, the compounds have an  $ED_{50}$  of less than 5 mg/kg in the test “Maximum electroshock” which is described below.

25 According to one particular aspect of the invention, the compounds have an  $ED_{50}$  of less than 5 mg/kg in the “Electrical seizure -threshold test” and “Chemical seizure -threshold test” which is described below.

Some compounds have few or clinically insignificant side effects. Some of the  
30 compounds are thus tested in models of the unwanted sedative, hypothermic and ataxic actions of the compounds.

Some of the compounds have a large therapeutic index between anticonvulsant efficacy and side-effects such as impairment of locomotor activity or ataxic effects as measured by performance on a rotating rod. This means that the compounds will expectedly be well tolerated in patients permitting high doses to be used before side effects are seen. Thereby compliance with the therapy will expectedly be good and administration of high doses may be permitted making the treatment more efficacious in patients who would otherwise have side effects with other medications.

## 10 Definitions

The term heteroatom refers to a nitrogen, oxygen or sulphur atom.

Halogen means fluoro, chloro, bromo or iodo.

15 The expressions C<sub>1-6</sub>-alk(en/yn)yl and C<sub>1-6</sub>-alk(an/en/yn)yl mean a C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl or a C<sub>2-6</sub>-alkynyl group.

The term C<sub>1-6</sub>-alkyl refers to a branched or unbranched alkyl group having from one to six carbon atoms inclusive, including but not limited to methyl, ethyl, 1-propyl, 20 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-2-dimethyl-1-propyl and 2-methyl-1-propyl.

Similarly, C<sub>2-6</sub>-alkenyl and C<sub>2-6</sub>-alkynyl, respectively, designate such groups having from two to six carbon atoms, including one double bond and one triple bond 25 respectively, including but not limited to ethenyl, propenyl, butenyl, ethynyl, propynyl and butynyl.

The expressions C<sub>1-4</sub>-alkyl and C<sub>1-4</sub>-alkanyl refer to a branched or unbranched alkyl group having from one to four carbon atoms inclusive, including but not limited to 30 methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl and 2-methyl-1-propyl.

The expression C<sub>1-3</sub>-alk(en/yn)yl means a C<sub>1-3</sub>-alkyl, C<sub>2-3</sub>-alkenyl or a C<sub>2-3</sub>-alkynyl group.

5 The term C<sub>1-3</sub>-alkyl refers to a branched or unbranched alkyl group having from one to three carbon atoms inclusive, including but not limited to methyl, ethyl, 1-propyl and 2-propyl.

Similarly, C<sub>2-3</sub>-alkenyl and C<sub>2-3</sub>-alkynyl, respectively, designate such groups having from two to three carbon atoms, including one double bond and one triple bond  
10 respectively, including but not limited to ethenyl, propenyl, ethynyl and propynyl.

The expressions C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(an/en)yl mean a C<sub>3-8</sub>-cycloalkyl- or cycloalkenyl group.

15 The term C<sub>3-8</sub>-cycloalkyl designates a monocyclic or bicyclic carbocycle having three to eight C-atoms, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, etc.

The expressions C<sub>3-6</sub>-cycloalk(en)yl and C<sub>3-6</sub>-cycloalk(an/en)yl mean a  
20 C<sub>3-6</sub>-cycloalkyl- or cycloalkenyl group.

The term C<sub>3-6</sub>-cycloalkyl designates a monocyclic or bicyclic carbocycle having three to six C-atoms, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, etc.

25 The term C<sub>3-8</sub>-cycloalkenyl designates a monocyclic or bicyclic carbocycle having three to eight C-atoms and including one double bond.

The expression C<sub>5-8</sub>-cycloalk(en)yl means a C<sub>5-8</sub>-cycloalkyl- or cycloalkenyl group.

30 The term C<sub>5-8</sub>-cycloalkyl designates a monocyclic or bicyclic carbocycle having five to eight C-atoms, including but not limited to cyclopentyl, cyclohexyl, etc.

The term C<sub>5-8</sub>-cycloalkenyl designates a monocyclic or bicyclic carbocycle having five to eight C-atoms and including one or two double bonds.

In the term C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and

5 C<sub>1-6</sub>-alk(en/yn)yl are as defined above.

The term Ar refers to optionally substituted aromatic systems of 5-10 carbon atoms, wherein 0, 1, 2, 3 or 4 carbon atoms may be replaced with independently selected heteroatoms. Examples of such Ar groups are optionally substituted phenyl,

10 optionally substituted naphthyl, optionally substituted thiophene, optionally substituted furan, optionally substituted thiazole, optionally substituted pyridine, optionally substituted pyrimidine, optionally substituted pyrrole and optionally substituted oxazole. Ar may be substituted with one or more substituents independently being hydroxy, halogen, C<sub>1-6</sub>-alk(en/yn)yl,

15 C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(an/en/yn)oxy, C<sub>3-8</sub>-alk(an/en/yn)oxy, acyl, cyano, -CO-NH-C<sub>1-6</sub>-alk(en/yn)yl, -CO-N(C<sub>1-6</sub>-alk(en/yn)yl)<sub>2</sub>, -NH-C<sub>1-6</sub>-alk(en/yn)yl, -N(C<sub>1-6</sub>-alk(en/yn)yl)<sub>2</sub>, -NH<sub>2</sub>, -S-C<sub>1-6</sub>-alk(en/yn)yl, -SO<sub>2</sub>-C<sub>1-6</sub>-alk(en/yn)yl, -SO<sub>2</sub>N(C<sub>1-6</sub>-alk(en/yn)yl)<sub>2</sub>, -SO<sub>2</sub>NH-C<sub>1-6</sub>-alk(en/yn)yl and -SO<sub>2</sub>O-C<sub>1-6</sub>-alk(en/yn)yl; or  
20 two substituents may together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms. Such two ringforming substituents may be adjacent and may together form:

-(CH<sub>2</sub>)<sub>n\*\*</sub>-CH<sub>2</sub>-, -CH=CH-(CH<sub>2</sub>)<sub>m\*\*</sub>-, -CH<sub>2</sub>-CH=CH-(CH<sub>2</sub>)<sub>p\*\*</sub>-,  
-(CH<sub>2</sub>)<sub>n\*\*</sub>-O-, -O-(CH<sub>2</sub>)<sub>m\*\*</sub>-O-, -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>p\*\*</sub>-O-, -CH<sub>2</sub>-O-CH<sub>2</sub>-O-CH<sub>2</sub>-,  
25 -(CH<sub>2</sub>)<sub>n\*\*</sub>-S-, -S-(CH<sub>2</sub>)<sub>m\*\*</sub>-S-, -CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>p\*\*</sub>-S-, -CH<sub>2</sub>-S-CH<sub>2</sub>-S-CH<sub>2</sub>-,  
-(CH<sub>2</sub>)<sub>n\*\*</sub>-NH-, -NH-(CH<sub>2</sub>)<sub>m\*\*</sub>-NH-, -CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>p\*\*</sub>-NH-, -CH=CH-NH-,  
-O-(CH<sub>2</sub>)<sub>m\*\*</sub>-NH-, -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>p\*\*</sub>-NH- or -O-(CH<sub>2</sub>)<sub>p\*\*</sub>-NH-CH<sub>2</sub>-,  
-S-(CH<sub>2</sub>)<sub>m\*\*</sub>-NH-, -N=CH-NH-, -N=CH-O- or -N=CH-S-, wherein m\*\* is 1, 2 or 3,  
n\*\* is 2, 3 or 4 and p\*\* is 1 or 2.

30


As used herein, the term acyl refers to formyl, C<sub>1-6</sub>-alk(en/yn)ylcarbonyl, C<sub>3-8</sub>-cycloalk(en)ylcarbonyl, Ar-carbonyl, Ar-C<sub>1-6</sub>-alk(en/yn)ylcarbonyl or a C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl-carbonyl group, wherein C<sub>1-6</sub>-alk(en/yn)yl,

C<sub>3-8</sub>-cycloalk(en)yl and Ar are as defined above.

- The term halo-C<sub>1-6</sub>-alk(en/yn)yl designates C<sub>1-6</sub>-alk(en/yn)yl being substituted with one or more halogen atoms, including but not limited to trifluoromethyl. Similarly,
- 5 halo-C<sub>3-8</sub>-cycloalk(en)yl designates C<sub>3-8</sub>-cycloalk(en)yl being substituted with one or more halogen atoms and halo-C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, designates C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl being substituted with one or more halogen atoms.
- 10 The terms hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, C<sub>1-6</sub>-alk(an/en/yn)yoxy, C<sub>1-4</sub>-alkanyloxy, C<sub>2-6</sub>-alkenyloxy, C<sub>2-6</sub>-alkynyloxy, C<sub>3-8</sub>-alk(an/en/yn)yoxy, C<sub>1-6</sub>-alk(en/yn)ylcarbonyl, C<sub>3-8</sub>-alk(en/yn)ylcarbonyl, Ar-carbonyl, Ar-C<sub>1-6</sub>-alk(en/yn)ylcarbonyl,
- 15 C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)ylcarbonyl etc. designate such groups in which the C<sub>1-6</sub>-alk(en/yn)yl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-8</sub>-cycloalk(en)yl and Ar are as defined above.

- The term "two substituents together form a 5-8 membered saturated or unsaturated
- 20 ring, which optionally contains one or two heteroatoms," refers to aliphatic or aromatic carbocyclic or heterocyclic systems wherein the ring is formed by 5 to 8 atoms which may be substituted by one or more substituents independently being C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl.
- 25 The ring forming atoms are selected from 3-8 carbon atoms and 0-2 heteroatoms selected from N, S, or O. When the two ring forming substituents are attached to the same nitrogen atom, then said nitrogen atom becomes one of the atoms forming the ring. When two ring forming substituents are attached to an aliphatic or aromatic carbocyclic or heterocyclic group, then the two ringforming substituents are
- 30 conveniently attached adjacent to each other and the ring formed by the two substituents is fused to the aliphatic or aromatic carbocyclic or heterocyclic group.

Two ring forming substituents may together be represented by:



- $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ ,  $-(\text{CH}_2)_n-\text{O}-$ ,  $-\text{O}-(\text{CH}_2)_m-\text{O}-$ ,  $-\text{CH}_2-\text{O}-(\text{CH}_2)_p-\text{O}-$ ,  
 $-\text{CH}_2-\text{O}-\text{CH}_2-\text{O}-\text{CH}_2-$ ,  $-(\text{CH}_2)_n-\text{S}-$ ,  $-\text{S}-(\text{CH}_2)_m-\text{S}-$ ,  $-\text{CH}_2-\text{S}-(\text{CH}_2)_p-\text{S}-$ ,  
 $-\text{CH}_2-\text{S}-\text{CH}_2-\text{S}-\text{CH}_2-$ ,  $-(\text{CH}_2)_n-\text{NH}-$ ,  $-\text{NH}-(\text{CH}_2)_m-\text{NH}-$ ,  $-\text{CH}_2-\text{NH}-(\text{CH}_2)_p-\text{NH}-$ ,  
 $-\text{CH}=\text{CH}-\text{NH}-$ ,  $-\text{O}-(\text{CH}_2)_m-\text{NH}-$ ,  $-\text{CH}_2-\text{O}-(\text{CH}_2)_p-\text{NH}-$  or  $-\text{O}-(\text{CH}_2)_p-\text{NH}-\text{CH}_2-$ ,  
 $-\text{S}-(\text{CH}_2)_m-\text{NH}-$ ,  $-\text{N}=\text{CH}-\text{NH}-$ ,  $-\text{N}=\text{CH}-\text{O}-$  or  $-\text{N}=\text{CH}-\text{S}-$ , wherein  $m$  is 1, 2 or 3,  
 $n$  is 2, 3 or 4 and  $p$  is 1 or 2.

The salts of the invention are preferably pharmaceutically acceptable salts. Such salts include pharmaceutical acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.

The pharmaceutically acceptable salts of the invention are preferably acid addition salts.

Acid addition salts include salts of inorganic acids as well as organic acids.

The acid addition salts of the invention are preferably pharmaceutically acceptable salts of the compounds of the invention formed with non-toxic acids.

Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfamic, phosphoric and nitric acids and the like. Such acid addition salts can be formed by methods known to the person skilled in the art. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in *J. Pharm. Sci.* 1977, 66, 2, which is incorporated herein by reference.

Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, ethanesulfonic, tartaric, ascorbic, pantoic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, itaconic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-

bromotheophylline and the like. Further examples of pharmaceutical acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977,66,2, which is incorporated herein by reference.

- 5 Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like.

Examples of ammonium and alkylated ammonium salts include ammonium, methyl-, dimethyl-, trimethyl-, ethyl-, hydroxyethyl-, diethyl-, n-butyl-, sec-butyl-, tert-butyl-,  
10 tetramethylammonium salts and the like.

Also intended as pharmaceutical acceptable acid addition salts are the hydrates, which the present compounds are able to form.

- 15 The compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof are included within the scope of the invention.

- 20 Furthermore, when a double bond or a fully or partially saturated ring system is present in the molecule geometric isomers may be formed. It is intended that any geometric isomers, as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also  
25 intended to be included within the scope of the present invention.

Furthermore, some of the compounds of the present invention may exist in different tautomeric forms and it is intended that any tautomeric forms that the compounds are able to form are included within the scope of the present invention.

30

The compounds of this invention may exist in unsolvated as well as in solvated forms with solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

Some of the compounds of the present invention contain chiral centres and such compounds exist in the form of isomers (i.e. enantiomers). The invention includes all such isomers and any mixtures thereof including racemic mixtures.

- 5 Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds of the present
- 10 invention can also be resolved into their optical antipodes, e.g. by fractional crystallization of d- or l- (tartrates, mandelates or camphorsulphonate) salts. The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives.
- 15 Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).
- 20 Optically active compounds can also be prepared from optically active starting materials.

The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming

25 pharmacologically active substances. In general, such prodrugs will be functional derivatives of the compounds of the general formulae **I**, **XI**, **XII**, **XIII**, **XIV** or **XV**, which are readily convertible in vivo into the required compound of the formulae **I**, **XI**, **XII**, **XIII**, **XIV** or **XV**. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs",

30 ed. H. Bundgaard, Elsevier, 1985.

The invention also encompasses active metabolites of the present compounds.

Whenever mentioned in relation to the compounds of the formulae **I, XI, XII, XIII, XIV** or **XV**, the terms epilepsy and epilepsies embrace any of the epilepsies, epileptic syndromes and epileptic seizures referred to in International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Commission on Classification and Terminology of the International League Against Epilepsy. *Epilepsia* **1981** 22: 489-501 and in International League Against Epilepsy: Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. *Epilepsia* **1989** 30(4): 389-399.

Whenever mentioned in relation to the compounds of the formulae **I, XI, XII, XIII, XIV** or **XV**, the term anxiety disorders embraces conditions and diseases related to panic attack, agoraphobia, panic disorder with agoraphobia, panic disorder without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorders, generalized anxiety disorder, anxiety disorder due to general medical condition, substance-induced anxiety disorder, separation anxiety disorder, adjustment disorders and anxiety disorder not otherwise specified as defined by American Psychiatric Association *Diagnostic and statistical manual of mental disorders*, 4ed **1994**: 110-113, 393-444 and 623-627.

### **Pharmaceutical compositions**

The compounds of this invention are generally utilized as the free base or as a pharmaceutically acceptable salt thereof. Representative examples are mentioned above.

If desired, the pharmaceutical composition of the invention may comprise the compound of formula I in combination with further pharmacologically active substances such as those described in the foregoing.

The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.

The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19 Edition, Gennaro, Ed., Mack  
5 Publishing Co., Easton, PA, 1995.

The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and  
10 parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.

15 Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.

20

Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.

25 Pharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.

30 Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.

The pharmaceutical compositions of this invention or those which are manufactured in accordance with this invention may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection. For preparing such compositions, methods well known in the art may be used, and any pharmaceutically acceptable carriers, diluents, excipients or other additives normally used in the art may be used.

A typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.

The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain from 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, and more preferred from about 0.5 mg to about 200 mg.

For parenteral routes such as intravenous, intrathecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administration.

The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. One example is a base addition salt of a compound having the utility of a free acid. When a compound of the invention contains a free acid such salts may be prepared in a conventional manner by treating a solution or suspension of a free acid of the compound of the invention with a chemical equivalent of a pharmaceutically acceptable base. Representative examples are mentioned above.

- For parenteral administration, solutions of the novel compounds of the invention in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
- 10 Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to a desired volume, sterilising the solution and filling it in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
- 15 Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents.
- Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, agar, pectin, acacia, stearic acid and lower alkyl ethers of cellulose corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like.
- Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.
- 25 Examples of liquid carriers are syrup, peanut oil, olive oil, phospho lipids, fatty acids, fatty acid amines, polyoxyethylene and water. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
- 30

The pharmaceutical compositions formed by combining the novel compounds of the invention and the pharmaceutical acceptable carriers are then readily administered in a

variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

- 5 Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include one or more suitable excipients. Furthermore, the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous  
10 liquid, or an oil-in-water or water-in-oil liquid emulsion.

If a solid carrier is used for oral administration, the preparation may be tablette, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge.

- 15 The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.

- If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft  
20 gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

- If desired, the pharmaceutical composition of the invention may comprise the compound of the formulae **I, XI, XII, XIII, XIV** or **XV** in combination with further  
25 pharmacologically active substances such as those described in the foregoing.

Typical examples of recipes for the formulation of the invention are as follows:

- |    |                                                                                       |        |        |
|----|---------------------------------------------------------------------------------------|--------|--------|
| 1) | Tablets containing 5.0 mg of a compound of the invention calculated as the free base: |        |        |
| 30 | Compound of formulae <b>I, XI, XII, XIII, XIV</b> or <b>XV</b>                        |        | 5.0 mg |
|    | Lactose                                                                               | 60 mg  |        |
|    | Maize starch                                                                          | 30 mg  |        |
|    | Hydroxypropylcellulose                                                                | 2.4 mg |        |


|    |    |                                                                                       |          |        |
|----|----|---------------------------------------------------------------------------------------|----------|--------|
|    |    | Microcrystalline cellulose                                                            | 19.2 mg  |        |
|    |    | Croscarmellose Sodium Type A                                                          | 2.4 mg   |        |
|    |    | Magnesium stearate                                                                    | 0.84 mg  |        |
| 5  | 2) | Tablets containing 0.5 mg of a compound of the invention calculated as the free base: |          |        |
|    |    | Compound of formulae <b>I, XI, XII, XIII, XIV</b> or <b>XV</b>                        | 0.5 mg   |        |
|    |    | Lactose                                                                               | 46.9 mg  |        |
|    |    | Maize starch                                                                          | 23.5 mg  |        |
| 10 |    | Povidone                                                                              | 1.8 mg   |        |
|    |    | Microcrystalline cellulose                                                            | 14.4 mg  |        |
|    |    | Croscarmellose Sodium Type A                                                          | 1.8 mg   |        |
|    |    | Magnesium stearate                                                                    | 0.63 mg  |        |
| 15 | 3) | Syrup containing per millilitre:                                                      |          |        |
|    |    | Compound of formulae <b>I, XI, XII, XIII, XIV</b> or <b>XV</b>                        |          | 25 mg  |
|    |    | Sorbitol                                                                              | 500 mg   |        |
|    |    | Hydroxypropylcellulose                                                                | 15 mg    |        |
|    |    | Glycerol                                                                              | 50 mg    |        |
| 20 |    | Methyl-paraben                                                                        | 1 mg     |        |
|    |    | Propyl-paraben                                                                        | 0.1 mg   |        |
|    |    | Ethanol                                                                               | 0.005 mL |        |
|    |    | Flavour                                                                               | 0.05 mg  |        |
|    |    | Saccharin sodium                                                                      | 0.5 mg   |        |
| 25 |    | Water                                                                                 | ad 1 mL  |        |
|    | 4) | Solution for injection containing per millilitre:                                     |          |        |
|    |    | Compound of formulae <b>I, XI, XII, XIII, XIV</b> or <b>XV</b>                        |          | 0.5 mg |
|    |    | Sorbitol                                                                              | 5.1 mg   |        |
| 30 |    | Acetic Acid                                                                           | 0.05 mg  |        |
|    |    | Saccharin sodium                                                                      | 0.5 mg   |        |
|    |    | Water                                                                                 | ad 1 mL  |        |

### Preparation of the compounds of the invention


The compounds of the invention of the general formula I, wherein  $R^1$ ,  $R^{1'}$ ,  $R^2$ ,  $R^{2'}$ ,  $R^3$ , U, Y, X, Z, q and s are as defined above may be prepared by the methods as represented in the schemes and as described below:

5


Scheme A:



Scheme B:



Scheme C:



In the compounds of general formulae **II**, **IIIa**, **IIIb**, **IV**, **V**, **XX**, **XXI**, **XXII**, **XXIII**, **XXIV**, **XXV**, **XXVI**, **XXVII** and **XXVIII**

**R<sup>1</sup>**, **R<sup>1'</sup>**, **R<sup>2</sup>**, **R<sup>2'</sup>**, **R<sup>3</sup>**, **U**, **Y**, **X**, **Z**, **q** and **s** are as defined under formula **I**, with the proviso that **R<sub>1</sub>** is not acyl in compounds of general formulae **XXII**, **XXIII**, **XXIV** and **XXV**.

Compounds of the general formulae **II**, **XX**, **XXIII**, **XXIV** and **XXVI** are either obtained from commercial sources, or prepared by standard methods known to chemists skilled in the art.

Compounds of the general formulae **IIIa** and **IIIb** are either obtained from commercial sources, or prepared by standard methods known to chemists skilled in the art as outlined below.

Compounds of the general formula **XXII**, may be prepared by reacting suitably substituted p-bromo-anilines or p-iodo-anilines of general formula **XX** with suitable electrophilic reagents, such as suitably substituted acid chlorides, acid bromides, acid iodides, sulfonyl chlorides, carbamoyl chlorides, chloro formates, isocyanates and with or without the addition of bases, such as pyridine, trialkyl amines, potassium carbonate, magnesium oxide or lithium-, sodium-, or potassium alcoholates, in a suitable solvent, such as ethyl acetate, dioxane, tetrahydrofuran, acetonitrile, or diethyl ether, at a suitable temperature, such as room temperature or reflux temperature. These derivatives of general formula **XXI** are then subjected to an acid-base reaction at the NH-function using an alkylmagnesium halide, such as methylmagnesium halide, isopropylmagnesium halide, or using a dialkylmagnesium, such as dibutylmagnesium, as the base, in a suitable solvent such as tetrahydrofuran or diethylether at a suitable temperature such as -30 °C or 0 °C. The acid-base reaction is then *in situ* followed by a lithium-halogen exchange by the addition of an alkyllithium such as n-butyllithium, sec-butyllithium or tert-butyllithium in a suitable solvent such as tetrahydrofuran or diethylether at a suitable temperature such as -78 °C or 0 °C. The organometallic species are then reacted with a suitable formylating reagent such as DMF or a suitable acylating reagent such as acetylchloride. For general references see Wakefield (B. J. Wakefield, "Organomagnesium Methods in

Organic Synthesis", Academic Press, 1995) and Brandsma & Verkruijsse (L. Brandsma and H. D. Verkruijsse, "Preparative Polar Organometallic Chemistry", Springer-Verlag, 1987).

- 5 Alternatively, compounds of the general formula **XXII** may be prepared by palladium catalysed C-N bond-forming reaction between suitably substituted p-bromo or p-iodo derivatives of general formula **XXIII** and suitably substituted amides or carbamates, as described by S. L. Buchwald et al. (J. Yin and S. L. Buchwald, Organic Letters, **2000**, 2, 1101).

10

- Alternatively, compounds of the general formula **XXII** may be prepared by reacting suitably substituted anilines of general formula **XXIV** with suitable electrophilic reagents, such as suitably substituted acid chlorides, acid bromides, acid iodides, sulfonyl chlorides, carbamoyl chlorides, chloro formates, isocyanates and with or  
15 without the addition of bases, such as pyridine, trialkyl amines, potassium carbonate, magnesium oxide or lithium-, sodium-, or potassium alcoholates, in a suitable solvent, such as ethyl acetate, dioxane, tetrahydrofuran, acetonitrile or diethyl ether, at a suitable temperature, such as room temperature or reflux temperature.

- 20 Compounds of general formula **XXV** may be prepared by nitration of compounds of formula **XXII**, in which (U)<sub>s</sub>-R<sup>2</sup> is hydrogen, under standard nitrating conditions, such as acetic acid anhydride/nitric acid, sulphuric acid/nitric acid, sulfuric acid/sodium or potassium nitrate, trifluoroacetic acid/sodium or potassium nitrate at a suitable temperature such as 0 °C or room temperature.

25

- Compounds of general formula **XXVII** may be prepared by reacting compounds of general formula **XXVI** with suitable electrophilic reagents, such as suitably substituted acid chlorides, acid bromides, acid iodides, sulfonyl chlorides, carbamoyl chlorides, chloro formates, isocyanates and with or without the addition of bases, such  
30 as pyridine, trialkyl amines, potassium carbonate, magnesium oxide or lithium-, sodium-, or potassium alcoholates, in a suitable solvent, such as ethyl acetate, dioxane, tetrahydrofuran, acetonitrile or diethyl ether, at a suitable temperature, such as room temperature or reflux temperature.

Compounds of general formula **XXVIII** may be prepared from compounds of the general formula **XXVII** by radical halogenation reactions known to the chemist skilled in the art, such as reaction with N-bromosuccinimide and dibenzoylperoxide, in a suitable solvent, such as tetrachloromethane or benzene at a suitable temperature, such as reflux temperature.

Some compounds of general formula **V** may be prepared by reductive amination reactions of compounds of the general formula **XXV**, known to the chemist skilled in the art, with amines of type Y-NH<sub>2</sub>, using reducing agents, such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid or hydrochloric acid, at a suitable temperature.

Alternatively, compounds of general formula **XXV** can be reacted with amines of type Y-NH<sub>2</sub>, in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, dioxane, xylene or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid, at a suitable temperature, to form imines, that can be isolated by crystallisation or by evaporation of the solvent. The imines can then be reduced using reducing agents, such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid, at a suitable temperature, to give compounds of the general formula **V**.

Alternatively, some compounds of the general formula **V** may be prepared by the reaction of compounds of the general formula **XXVIII** with amines of type Y-NH<sub>2</sub>, for example 4-tert-butylaniline, in a suitable solvent, such as tetrahydrofuran, dioxane or N,N-dimethylformamide, with or without addition of bases, such as trialkyl amines or potassium carbonate, at a suitable temperature.

30

Alternatively, some compounds of general formula **V** may be prepared by nitration of compounds of general structure **IV**, in which (U)<sub>s</sub>-R<sup>2</sup> is hydrogen, under standard nitrating conditions, such as acetic acid anhydride/nitric acid, sulphuric acid/nitric

acid, sulfuric acid/sodium or potassium nitrate, trifluoroacetic acid/sodium or potassium nitrate at a suitable temperature such as 0 °C or room temperature, followed by reaction with amines of type Y-NH<sub>2</sub>, for example 4-tert-butylaniline, in a suitable solvent, such as tetrahydrofuran, dioxane or N,N-dimethylformamide, with or without  
5 addition of bases, such as trialkyl amines or potassium carbonate, at a suitable temperature.

Alternatively, appropriate carboxylic acids are reduced with appropriate reducing agents, such as borane, and carboxylic acid esters are reduced with appropriate  
10 reducing agents, such as diisobutyl aluminium hydride. The resulting benzylic alcohols are then reacted with a suitable oxidant, such as tetrapropylammonium perruthenate/N-methylmorpholin-N-oxide, pyridinium chlorochromat or dimethylsulfoxide/ oxalylchloride, to give compounds of general formula **IIIb**.  
Additionally, for further variation of R<sup>2</sup>, compounds of the general formula **IIIa**,  
15 wherein R<sup>2</sup> = methyl, U = oxygen, and s = 1, can be demethylated by methods known to chemists skilled in the art, such as treatment with boron tribromide in a suitable solvent, such as dichloromethane, at a suitable temperature, such as 0 °C or room temperature. The resulting phenols can then be transformed into compounds of the general formula **IIIa**, wherein U = oxygen, and s = 1, by methods known to chemists  
20 skilled in the art. Such methods include: (a) the reaction with electrophiles, such as alkyl chlorides, alkyl bromides, alkyl iodides, benzyl chlorides, benzyl bromides, benzyl iodides, carbonic acid chlorides, carbonic acid bromides, or carbonic acid anhydrides in the presence of suitable bases, such as potassium carbonate, in a suitable solvent, such as tetrahydrofuran, N,N-dimethylformamide, or 1,2-  
25 dichloroethane, at suitable temperatures, such as room temperature or reflux temperature; (b) the reaction with alkyl, benzylic, or heteroarylalkyl alcohols under conditions known as the *Mitsunobu* reaction (O. Mitsunobu *Synthesis* **1981**, 1).

Alternatively, compounds of the general formula **IIIa** may be prepared by the reaction  
30 of compounds of the general structure **II** with suitable electrophilic reagents, such as suitably substituted acid chlorides, acid bromides, acid iodides, sulfonyl chlorides, carbamoyl chlorides, chloro formates, isocyanates and with or without the addition of bases, such as pyridine, trialkyl amines, potassium carbonate, magnesium oxide or

lithium-, sodium-, or potassium alcoholates, in a suitable solvent, such as ethyl acetate, dioxane, tetrahydrofuran, acetonitrile or diethyl ether, at a suitable temperature, such as room temperature or reflux temperature.

- 5 Compounds of the general formula IV may be prepared from compounds of the general formula IIIa by radical halogenation reactions known to the chemist skilled in the art, such as reaction with N-bromosuccinimide and dibenzoylperoxide, in a suitable solvent, such as tetrachloromethane or benzene at a suitable temperature, such as reflux temperature.

10

Some compounds of the general formula I may be prepared by the reaction of compounds of the general formula IV with amines of type Y-NH<sub>2</sub>, for example 4-tert-butylaniline, in a suitable solvent, such as tetrahydrofuran, dioxane or N,N-dimethylformamide, with or without addition of bases, such as trialkyl amines or potassium carbonate, at a suitable temperature.

15

Compounds of the general formula I can be prepared by reductive amination reactions of compounds of the general formulae IIIb and XXII, known to the chemist skilled in the art, with amines of type Y-NH<sub>2</sub>, using reducing agents, such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid or hydrochloric acid, at a suitable temperature.

20

- 25 Alternatively, compounds of the general formulae IIIb and XXII can be reacted with amines of type Y-NH<sub>2</sub>, in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, dioxane, xylene or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid, at a suitable temperature, to form imines, that can be isolated by crystallisation or by evaporation of the solvent. The imines can then be reduced using reducing agents, such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or mixtures thereof, with or without addition of

30

catalytic amounts of acid, such as acetic acid, at a suitable temperature, to give compounds of the general formula I.

Alternatively, compounds of the general formula I may be prepared by the reaction of  
5 compounds of the general formula V with a suitable reducing agent, such as iron or zinc powder in aqueous hydrochloric acid or in alcoholic ammonium chloride or aqueous sodium dithionite, in a suitable solvent, such as tetrahydrofuran or ethanol.

To obtain compounds of the general formula I, where U is  $\text{NR}^{2'}$  and s is 1 and  $\text{R}^2$  and  
10 optionally  $\text{R}^{2'}$  are not hydrogen, a protecting group, such as tertbutoxycarbonyl, is introduced at the benzylic nitrogen in compounds of the general formula V, before the reduction of the nitro group, by methods known to the chemist skilled in the art. This protecting group is cleaved by known methods, after the introduction of  $\text{R}^2$  and optionally  $\text{R}^{2'}$ , said introduction is accomplished by using one or more of the  
15 following methods:

Introduction of  $\text{R}^2$  by a reductive alkylation procedure using suitable aldehydes and reducing agents, such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or  
20 mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid, at a suitable temperature, as described above.

Optional introduction of  $\text{R}^{2'}$  by an additional reductive alkylation procedure using suitable aldehydes and reducing agents, such as sodium borohydride or sodium  
25 cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid, at a suitable temperature, as described above.

Alternatively,  $\text{R}^{2'}$  or  $\text{R}^2$  may be introduced by an acylation reaction using suitable  
30 electrophilic reagents, such as acid chlorides, acid bromides, acid iodides, sulfonyl chlorides, and alkyl formates with the addition of bases, such as trialkyl amines, potassium carbonate, magnesium oxide or lithium-, sodium-, or potassium

alcoholates, in a suitable solvent, such as ethyl acetate, dioxane, tetrahydrofuran, acetonitrile or diethyl ether, at a suitable temperature, as described above.

## 5 Examples

Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with IonSpray source and Shimadzu LC-8A/SLC-10A LC system. Column: 30 X 4.6 mm Waters Symmetry C18 column with 3.5  $\mu$ m particle size; Solvent system: A = water/trifluoroacetic acid (100:0.05) and B = water/acetonitrile/trifluoroacetic acid  
10 (5:95:0.03); Method: Linear gradient elution with 90% A to 100% B in 4 minutes and with a flow rate of 2 mL/min. Purity is expressed in % and was determined by integration of the UV (254 nm) and ELSD trace. The retention times (RT) are expressed in minutes.

15  $^1\text{H}$  NMR spectra were recorded at 500.13 MHz and  $^{13}\text{C}$  NMR spectra were recorded at 125.76 MHz, both on a Bruker Avance DRX500 instrument. Deuterated chloroform (99.8%D) or dimethyl sulfoxide (99.8%D) were used as solvents. TMS was used as internal reference standard. Chemical shift values are expressed in ppm-values. The following abbreviations are used for multiplicity of NMR signals: s = singlet, d =  
20 doublet, t = triplet, q = quartet, qu = quintet, h = heptet, dd = double doublet, dt = double triplet, dq = double quartet, tt = triplet of triplets, m = multiplet and br = broad.

## Preparation of intermediates

### *(4-Methyl-2-nitrophenyl)-carbamic acid ethyl ester*

25 4-Methyl-2-nitroaniline (45.7 g, 0.30 mol) was dissolved in tetrahydrofuran (350 mL) and  $\text{K}_2\text{CO}_3$  (50 g, 0.36 mol) was added. Ethyl chloroformate (39.1 g, 0.36 mol) dissolved in THF (50 mL) was added and the solution refluxed for 18 hours. The mixture was cooled to ambient temperature and the solid filtered off. The solution was concentrated *in vacuo* and the resulting solid recrystallised from ethanol to give 47.1 g  
30 (70 %) of the title compound as yellow crystals. LC/MS ( $m/z$ ) 224.9 ( $\text{MH}^+$ ); RT = 3.08.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 2.38 (s, 3H); 4.28 (q, 2H); 7.42 (d, 1H); 8.00 (s, 1H); 8.45 (d, 1H); 9.70 (s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.4, 20.4, 61.9, 120.7, 125.6, 132.4, 133.1, 135.9, 136.9, 153.3.

The following intermediates were prepared analogously:

*(4-Bromo-2-chlorophenyl)carbamic acid ethyl ester*

LC/MS (m/z) 278.9 ( $M^+$ ); RT = 3.45.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.38 (t, 3H); 4.30 (q, 2H);  
5 7.10 (br s, 1H); 7.42 (d, 1H); 7.55 (s, 1H); 8.12 (d, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.9,  
62.2, 115.5, 121.3, 123.0, 131.2, 131.8, 134.5, 153.4.

*(4-Bromo-2-fluorophenyl)carbamic acid ethyl ester*

LC/MS (m/z) 262.8 ( $M^+$ ); RT = 3.21.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 4.27 (q, 2H);  
10 6.80 (br s, 1H); 7.30 (br m, 2H); 8.05 (br m, 1H).

*(4-Bromo-2-methylphenyl)carbamic acid ethyl ester*

LC/MS (m/z) 258.6 ( $M^+$ ); RT = 3.67.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.38 (t, 3H); 2.35 (s, 3H);  
15 4.30 (q, 2H); 7.05 (br s, 1H); 7.50 (d, 1H); 7.65 (s, 1H); 8.20 (d, 1H).

*(4-Acetylphenyl)carbamic acid ethyl ester*

LC/MS (m/z) 207.8 ( $M^+$ ); RT = 2.16.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 2.60 (s, 3H);  
20 4.27 (q, 2H); 7.00 (br s, 1H); 7.50 (d, 2H); 7.95 (d, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.9,  
26.8, 62.0, 118.0, 130.3, 132.5, 142.9, 153.5, 197.4.

*N-(4-bromo-2-chlorophenyl)butyramide*

LC/MS (m/z) 277.8 ( $M\text{H}^+$ ); RT = 3.00.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 0.95 (t, 3H); 1.70 (m, 2H);  
25 2.35 (t, 2H); 7.32 (d, 1H); 7.45 (s, 1H); 7.50 (br s, 1H); 8.25 (d, 1H).  $^{13}\text{C}$  NMR  
( $\text{CDCl}_3$ ): 14.1, 19.8, 40.3, 117.1, 122.9, 123.5, 131.2, 131.8, 134.3, 171.6.

*N-(4-bromophenyl)butyramide*

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.80 (m, 2H); 2.35 (t, 2H); 7.15 (br s, 1H); 7.45 (br m,  
4H).

30 *N-(4-bromo-2-fluorophenyl)butyramide*

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.75 (m, 2H); 2.45 (t, 2H); 7.30 (br m, 3H); 8.30 (br  
m, 1H).

*N-(4-bromo-2-methylphenyl)butyramide*

LC/MS (m/z) 256.0 ( $M^+$ ); RT = 2.60.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.80 (m, 2H); 2.25 (s, 3H); 2.40 (t, 2H); 6.90 (br s, 1H); 7.35 (br m, 2H); 7.80 (br d, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 13.8, 17.6, 19.0, 39.5, 180.0, 124.9, 127.0, 130.5, 132.7, 133.1, 134.8, 171.3.

5

*(4-Bromomethyl-2-nitrophenyl)-carbamic acid ethyl ester*

(4-Methyl-2-nitrophenyl)-carbamic acid ethyl ester (22.4 g, 0.10 mol) is dissolved in  $\text{CCl}_4$  (300 mL) and N-bromosuccinimide (17.8 g, 0.10 mmol) is added followed by  
10 dibenzoylperoxid (0.73 g, 0.003 mol). The mixture is stirred at reflux for 12 hours and then cooled to ambient temperature. The mixture was filtered and the solution concentrated *in vacuo*. The remaining solid was recrystallised from methanol to give 17.0 g (56 %) of the title compound as bright yellow crystals. LC/MS (m/z) 304.3 ( $M\text{H}^+$ ); RT = 3.22.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.38 (t, 3H); 4.29 (q, 2H); 4.50 (s, 2H); 7.65 (d,  
15 1H); 8.25 (s, 1H); 8.58 (d, 1H); 9.85 (s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.8, 31.5, 62.5, 121.6, 126.5, 132.4, 135.9, 136.0, 136.8, 153.4.

*(2-Chloro-4-formylphenyl)carbamic acid ethyl ester*

To (4-Bromo-2-chlorophenyl)carbamic acid ethyl ester (6.1 g, 21.9 mmol) dissolved  
20 in dry tetrahydrofuran (100 mL), kept under an argon atmosphere and cooled on an ice bath, was added dibutylmagnesium (11 mL of a 1.0 M solution in heptane, 11 mmol) and the solution was stirred for 30 minutes. The solution was then cooled to  $-78^\circ\text{C}$  using an acetone/dry-ice bath and n-butyllithium (15 mL of a 1.6 M solution in hexane) was added over 30 minutes, while keeping the temperature below  $-70^\circ\text{C}$ .  
25 The mixture was stirred for 1 hour, and then DMF (3.2 g, 43.8 mmol) was added dropwise. The mixture was allowed to reach ambient temperature, stirred for 1 hour, and quenched by addition of aqueous ammoniumchloride (50 mL). The phases were separated and the organic phase was evaporated *in vacuo*. The product was purified by column chromatography using silica gel on a Flashmaster system eluting with  
30 heptane/ethyl acetate (linear gradient from 1:0 to 5:1). Fractions containing the product were pooled and evaporation *in vacuo* gave the title compound as a white solid (2.5 g, 50%)

LC/MS (m/z) 228.1 ( $M^+$ ); RT = 2.55.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.30 (t, 3H); 4.22 (q, 2H); 7.45 (br s, 1H); 7.70 (d, 1H); 7.85 (s, 1H); 8.38 (d, 1H); 9.80 (s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.4, 62.2, 118.9, 122.2, 129.9, 130.2, 131.7, 140.2, 152.7, 189.7.

5 The following intermediates were prepared analogously:

*(2-Fluoro-4-formylphenyl)carbamic acid ethyl ester*

LC/MS (m/z) 211.9 ( $M^+$ ); RT = 2.24.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.38 (t, 3H); 4.32 (q, 2H); 7.15 (br s, 1H); 7.60-7.72 (br m, 2H); 8.40 (br m, 1H); 9.90 (s, 1H).  $^{13}\text{C}$  NMR  
10 ( $\text{CDCl}_3$ ): 14.4, 62.1, 114.2, 119.1, 128.2, 131.5, 132.6, 150.7, 152.7, 190.0.

*(4-Formyl-2-methylphenyl)carbamic acid ethyl ester*

LC/MS (m/z) 207.8 ( $M^+$ ); RT = 2.18.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.38 (t, 3H); 2.40 (s, 3H); 4.30 (q, 2H); 6.70 (br s, 1H); 7.70 (d, 1H); 7.80 (s, 1H); 8.25 (d, 1H); 9.93 (s, 1H).  $^{13}\text{C}$   
15 NMR ( $\text{CDCl}_3$ ): 14.5, 17.5, 61.8, 118.6, 125.7, 130.1, 131.2, 131.4, 142.0, 153.1, 191.3.

*N-(4-formylphenyl)butyramide*

LC/MS (m/z) 192.0 ( $M^+$ ); RT = 1.94.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.00 (t, 3H); 1.80 (m, 2H);  
20 2.40 (t, 2H); 7.60 (br s, 1H); 7.72 (d, 2H); 7.85 (d, 2H); 9.95 (s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 13.7, 18.9, 39.8, 119.2, 131.2, 132.2, 143.6, 171.7, 191.1.

*N-(2-chloro-4-formylphenyl)butyramide*

LC/MS (m/z) 225.7 ( $M^+$ ); RT = 2.39.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.08 (t, 3H); 1.82 (m, 2H);  
25 2.50 (t, 2H); 7.80 (d, 1H); 7.90 (br s, 1H); 7.95 (s, 1H); 8.70 (d, 1H); 9.90 (s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 13.7, 18.8, 40.0, 120.6, 122.8, 129.6, 130.3, 132.2, 139.8, 171.5, 189.8.

*N-(2-fluoro-4-formylphenyl)butyramide*

LC/MS (m/z) 210.0 ( $M^+$ ); RT = 2.10.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.80 (m, 2H);  
30 2.45 (t, 2H); 7.60 (m, 1H); 7.70 (br m, 3H); 8.65 (m, 1H); 9.90 (s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 13.7, 18.8, 39.8, 113.9, 120.8, 128.3, 132.2, 151.0, 152.9, 171.7, 190.0.

*N*-(4-formyl-2-methylphenyl)butyramide

LC/MS (m/z) 206.0 ( $M^+$ ); RT = 1.98.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.85 (m, 2H); 2.35 (s, 3H); 2.45 (t, 2H); 7.10 (br s, 1H); 7.70 (br m, 2H); 7.80 (br m, 1H); 8.35 (br m, 1H); 9.95 (s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 13.7, 17.6, 19.0, 39.8, 121.1, 127.0, 129.9, 131.2, 132.2, 141.7, 171.3, 191.3.

*(4-Formylphenyl)carbamic acid ethyl ester*

4-Bromobenzaldehyde (9.25 g, 50 mmol), ethyl carbamate (5.35 g, 60 mmol), bis(dibenzylideneacetone)palladium (288 mg, 1.0 mol%), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (435 mg, 1.5 mol%) and cesiumcarbonate (23.0 g, 70 mmol) was suspended in dry tetrahydrofuran (100 mL) under an argon atmosphere and the mixture was heated to 80 °C over night. After cooling to ambient temperature the mixture was diluted with ethyl acetate (100 mL), filtered and purified by filtration through a short plug of silica gel. Evaporation *in vacuo* gave the title compound as a yellow solid (9.3 g, 96.3%).

LC/MS (m/z) 193.7 ( $M^+$ ); RT = 2.12.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.28 (t, 3H); 4.20 (q, 2H); 6.95 (br s, 1H); 7.50 (d, 2H); 7.78 (d, 2H); 9.85 (s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.9, 62.2, 118.4, 131.7, 132.0, 144.2, 153.4, 191.4.

The following intermediate was prepared analogously:

*(4-Formyl-2-nitrophenyl)carbamic acid tert-butyl ester*

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.55 (s, 9H); 8.12 (d, 1H); 8.70 (s, 1H); 8.82 (d, 1H); 9.90 (s, 1H); 10.05 (br s, 1H).

*(4-Formyl-2-nitrophenyl)carbamic acid ethyl ester*

(4-Formylphenyl)carbamic acid ethyl ester (6.34 g, 32.8 mmol) was dissolved in concentrated sulphuric acid (150 mL) cooled to 0 °C using an ice bath. Sodium nitrate (2.92 g, 34.4 mmol) was added in small portions over 20 minutes. After complete addition the mixture was stirred 3 hours at 0 °C and then poured onto chrushed ice.

The yellow precipitate was filtered off, washed thoroughly with water and dried *in vacuo* to give 7.11g (91%) of the title compound.

LC/MS (m/z) 238.5 ( $M^+$ ); RT = 2.62.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.40 (t, 3H); 4.32 (q, 2H); 8.15 (d, 1H); 8.75 (s, 1H); 8.85 (d, 1H); 9.95 (s, 1H); 10.15 (br s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.7, 63.0, 121.2, 128.9, 130.5, 131.7, 135.6, 140.7, 153.0, 189.2.

5 The following intermediate was prepared analogously:

*(4-Acetyl-2-nitrophenyl)carbamic acid ethyl ester*

LC/MS (m/z) 252.8 ( $M^+$ ); RT = 2.69.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.40 (t, 3H); 2.65 (s, 3H); 4.35 (q, 2H); 8.22 (d, 1H); 8.75 (d, 1H); 8.85 (s, 1H); 10.10 (br s, 1H).  $^{13}\text{C}$  NMR  
10 ( $\text{CDCl}_3$ ): 14.7, 26.7, 62.9, 120.8, 127.0, 131.4, 135.4, 135.6, 139.6, 153.3, 195.2.

*(4'-Dimethylamino-5-formylbiphenyl-2-yl)carbamic acid ethyl ester*

(2-Bromo-4-formylphenyl)carbamic acid ethyl ester (0.50 g, 1.84 mmol), 4-dimethylamino-phenyl-boronic acid (0.90 g, 5.52 mmol) and palladium(II)acetate  
15 (0.040 g, 0.18 mmol) was suspended in acetone (15 mL) and 5 M potassium carbonate (2 mL, 10 mmol) was added. The mixture was heated to 125 °C for 10 minutes in a microwave oven. After cooling to ambient temperature, the mixture was filtered, concentrated *in vacuo* and purified by column chromatography using silica gel on a Flashmaster system eluting with heptane/ethyl acetate (linear gradient from 1:0 to  
20 3:1). Fractions containing the product were pooled and evaporation *in vacuo* gave the title compound as a yellow solid (260 mg, 45%).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.25 (t, 3H); 3.05 (s, 6H); 4.20 (q, 2H); 6.82 (d, 2H); 7.10 (br s, 1H); 7.21 (d, 2H); 7.70 (s, 1H); 7.82 (d, 1H); 8.40 (d, 1H); 9.95 (s, 1H).

25 The following intermediate was prepared analogously:

*(4'-Chloro-5-formylbiphenyl-2-yl)carbamic acid ethyl ester*

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.28 (t, 3H); 4.20 (q, 2H); 6.78 (br s, 1H); 7.30 (d, 2H); 7.50 (d, 2H); 7.70 (s, 1H); 7.88 (d, 1H); 8.45 (d, 1H); 9.95 (s, 1H).

*{4-[(4-tert-Butylphenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*  
(4-Bromomethyl-2-nitrophenyl)-carbamic acid ethyl ester (0.5 g, 1.65 mmol), 4-tert-butyl-aniline (0.28 g, 1.8 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.35 g, 2.5 mmol) were mixed in tetrahydrofuran (15 mL) and heated to reflux temperature for 12 hours. The mixture  
5 was cooled to ambient temperature, filtered and evaporated to dryness *in vacuo*. Purified by chromatography using silica gel on a Flashmaster system eluting with heptane/ethyl acetate (linear gradient from 1:0 to 5:1). Fractions containing the product were pooled and evaporated *in vacuo* to yield the title compound as a yellow solid (400 mg, 65%).

10 LC/MS (m/z) 372.2 (MH<sup>+</sup>); RT = 3.58, UV purity = 97.9, ELS purity = 98.1.

The following intermediates were prepared analogously:

*(2-Nitro-4-phenylaminomethylphenyl)-carbamic acid ethyl ester*

LC/MS (m/z) 315.0 (M<sup>+</sup>); RT = 3.12, UV purity = 92.1, ELS purity = 95.0.

15

*{2-Nitro-4-[(4-trifluoromethylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 383.1 (MH<sup>+</sup>); RT = 3.62, UV purity = 86.0, ELS purity = 98.2.

20 *{4-[(4-Chlorophenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 349.1 (M<sup>+</sup>); RT = 3.58, UV purity = 96.0, ELS purity = 98.7.

*[4-(Naphthalen-2-ylaminomethyl)-2-nitrophenyl]-carbamic acid ethyl ester*

LC/MS (m/z) 366.3 (MH<sup>+</sup>); RT = 3.62, UV purity = 87.9, ELS purity = 92.3.

25

*[2-Nitro-4-(p-tolylamino-methyl)-phenyl]-carbamic acid ethyl ester*

LC/MS (m/z) 330.1 (MH<sup>+</sup>); RT = 2.87, UV purity = 97.1, ELS purity = 98.4.

*{4-[(3-Fluorophenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*

30 LC/MS (m/z) 332.0 (M<sup>+</sup>); RT = 3.33, UV purity = 84.8, ELS purity = 96.1.

*{4-[(4-Fluorophenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 332.0 ( $M^+$ ); RT = 3.10, UV purity = 98.2, ELS purity = 98.8.  $^1H$  NMR ( $CDCl_3$ ): 1.33 (t, 3H); 4.00 (br s, 1H, NH); 4.28 (q, 2H); 4.33 (s, 2H); 6.52 (m, 2H); 6.88 (m, 2H); 7.65 (m, 1H); 8.20 (s, 1H); 8.55 (m, 1H); 9.78 (s, 1H, NH).

- 5 *{4-[(2-Fluorophenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 333.8 ( $MH^+$ ); RT = 3.41, UV purity = 93.8, ELS purity = 96.1.

*[4-(Biphenyl-4-ylaminomethyl)-2-nitrophenyl]-carbamic acid ethyl ester*

LC/MS (m/z) 392.3 ( $MH^+$ ); RT = 3.74, UV purity = 87.0, ELS purity = 94.5.

10

*{4-[(2,4-Difluorophenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 351.3 ( $M^+$ ); RT = 3.45, UV purity = 96.1, ELS purity = 97.2.

*{4-[(4-Methoxyphenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*

- 15 LC/MS (m/z) 346.1 ( $MH^+$ ); RT = 2.16, UV purity = 87.3, ELS purity = 96.9.

*{4-[(4-Cyclohexylphenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 397.2 ( $M^+$ ); RT = 3.87, UV purity = 95.8, ELS purity = 98.6.

- 20 *[4-(Indan-5-ylaminomethyl)-2-nitrophenyl]-carbamic acid ethyl ester*

LC/MS (m/z) 355.2 ( $M^+$ ); RT = 2.97, UV purity = 97.1, ELS purity = 99.2.

*{4-[(4-Isopropylphenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 358.1 ( $MH^+$ ); RT = 3.33, UV purity = 98.1, ELS purity = 99.3.

25

*{4-[(4-Butylphenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 371.8 ( $M^+$ ); RT = 3.10, UV purity = 92.3, ELS purity = 94.1.

*{4-[2-(4-Chloro-3-fluorophenyl)ethyl]-2-nitrophenyl}carbamic acid ethyl ester*

- 30 A solution of (4-formyl-2-nitrophenyl)carbamic acid ethyl ester (1.40 g, 5.88 mmol) and 4-chloro-3-fluoroaniline (0.86 g, 5.88 mmol) in dry toluene (30 mL) was refluxed for 12 hours, and the toluene was removed *in vacuo*. The solids were then redissolved in ethanol (30 mL) and acetic acid (3 mL) and treated with sodium cyanoborohydride

(1.50 g, 23.8 mmol). After stirring for 1 hour at ambient temperature the mixture was treated with a second batch of sodium borohydride (1.50 g, 23.8 mmol) and stirred for 3 hours. The reaction was quenched with aqueous sodium hydrogencarbonate (50 mL) and the precipitate filtered off, washed with water and dried *in vacuo* to give the title compound as a yellow solid (1.84 g, 85%).

LC/MS (m/z) 367.1 ( $M^+$ ); RT = 3.70, UV purity = 94.2, ELS purity = 97.7.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.38 (t, 3H); 4.15 (q, 2H); 4.28 (d, 2H); 4.65 (br, 1H); 6.28 (m, 2H); 7.05 (m, 1H); 7.55 (d, 1H); 8.10 (s, 1H); 8.50 (d, 1H); 9.70 (s, 1H).

The following intermediates were prepared analogously:

*{4-[(2,4-Dichlorophenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 4.25 (q, 2H); 4.40 (d, 2H); 4.82 (br t, 1H); 6.45 (d, 1H); 7.02 (d, 1H); 7.22 (m, 1H); 7.60 (d, 1H); 8.15 (m, 1H); 8.55 (d, 1H); 9.75 (br s, 1H).

*{4-[(2,3-Dichlorophenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.33 (t, 3H); 4.25 (q, 2H); 4.45 (d, 2H); 5.00 (br t, 1H); 6.40 (d, 1H); 6.80 (d, 1H); 6.98 (m, 1H); 7.60 (m, 1H); 8.17 (m, 1H); 8.55 (d, 1H); 9.70 (br s, 1H).

*{4-[(3,5-Dichlorophenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 4.20-4.40 (br m, 5H); 6.45 (s, 2H); 6.70 (m, 1H); 7.60 (d, 1H); 8.15 (m, 1H); 8.58 (d, 1H); 9.80 (br s, 1H).

*{4-[(3,4-Dichlorophenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.33 (t, 3H); 4.22-4.40 (m, 5H); 6.42 (dd, 1H); 6.65 (d, 1H); 7.20 (d, 1H); 7.58 (d, 1H); 8.15 (s, 1H); 8.55 (d, 1H); 9.80 (br s, 1H).

*{2-Nitro-4-[(3-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester*

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 4.27 (q, 2H); 4.40 (br m, 3H); 6.70 (d, 1H); 6.82 (br s, 1H); 6.98 (d, 1H); 7.22 (m, 1H); 7.62 (d, 1H); 8.20 (s, 1H); 8.55 (d, 1H); 9.75 (br s, 1H).

*{4-[(3-Fluoro-4-trifluoromethylphenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

LC/MS (m/z) 401.5 ( $M^+$ ); RT = 3.74, UV purity = 92.1, ELS purity = 98.5.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.28 (t, 3H); 4.15 (q, 2H); 4.25 (d, 2H); 4.60 (br, 1H); 6.18-6.28 (br m, 2H);  
5 7.32 (m, 1H); 7.50 (d, 1H); 8.05 (s, 1H); 8.45 (d, 1H); 9.70 (s, 1H).

*{4-[(3,4-Difluorophenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

LC/MS (m/z) 351.1 ( $M^+$ ); RT = 3.53, UV purity = 84.5, ELS purity = 98.2.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 4.20 (br, 1H); 4.28 (q, 2H); 4.35 (s, 2H); 6.22 (m, 1H); 6.40 (m,  
10 1H); 6.95 (m, 1H); 7.60 (d, 1H); 8.20 (s, 1H); 8.55 (d, 1H); 9.75 (s, 1H).

*{4-[(4-Cyanophenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

LC/MS (m/z) 340.5 ( $M^+$ ); RT = 3.20, UV purity = 85.6, ELS purity = 93.1.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.35 (t, 3H); 4.05 (br, 1H); 4.25 (q, 2H); 4.40 (s, 2H); 6.60 (d, 2H); 7.40 (d,  
15 2H); 7.55 (d, 1H); 8.15 (s, 1H); 8.55 (d, 1H); 9.77 (s, 1H).

*{4-[(4-Fluoro-3-trifluoromethylphenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

LC/MS (m/z) 401.0 ( $M^+$ ); RT = 3.74, UV purity = 92.7, ELS purity = 99.6.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.35 (t, 3H); 4.00 (br, 1H); 4.25 (q, 2H); 4.35 (s, 2H); 6.65 (m, 1H); 6.75 (m,  
20 1H); 7.00 (m, 1H); 7.60 (d, 1H); 8.15 (s, 1H); 8.55 (d, 1H); 9.80 (s, 1H).

*{4-[(3-Chloro-4-methylphenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

LC/MS (m/z) 364.1 ( $M^+$ ); RT = 3.87, UV purity = 95.4, ELS purity = 99.2.

25

*{4-[(3-Chlorophenylamino)methyl]-2-nitrophenyl}carbamic acid ethyl ester*

LC/MS (m/z) 351.2 ( $M^+$ ); RT = 3.58, UV purity = 92.3, ELS purity = 98.7.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.35 (t, 3H); 4.18-4.30 (m, 3H); 4.38 (s, 2H); 6.45 (d, 1H); 6.55 (s, 1H); 6.70 (d, 1H); 7.05 (m, 1H); 7.65 (d, 1H); 8.20 (s, 1H); 8.55 (d, 1H); 9.80 (br s, 1H).

30

*[2-Nitro-4-(m-tolylaminomethyl)phenyl]carbamic acid ethyl ester*

LC/MS (m/z) 330.1 ( $M^+$ ); RT = 3.20, UV purity = 96.6, ELS purity = 98.2.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.35 (t, 3H); 2.25 (s, 3H); 4.10 (m, 1H); 4.25 (q, 2H); 4.38 (m, 2H); 6.40 (d,

1H); 6.45 (s, 1H); 6.60 (d, 1H); 7.05 (m, 1H); 7.65 (d, 1H); 8.20 (s, 1H); 8.55 (d, 1H); 9.80 (br s, 1H).

*{4-[1-(4-Chlorophenylamino)ethyl]-2-nitrophenyl}carbamic acid ethyl ester*

5 LC/MS (m/z) 363.2 ( $M^+$ ); RT = 3.68, UV purity = 93.6, ELS purity = 98.0.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 1.55 (d, 3H); 4.10 (s, 1H); 4.22 (q, 2H); 4.45 (q, 1H); 6.38 (d, 2H); 7.05 (d, 2H); 7.60 (d, 1H); 8.15 (s, 1H); 8.55 (d, 1H); 9.72 (s, 1H).

*{2-Nitro-4-[1-(4-trifluoromethylphenylamino)ethyl]phenyl}carbamic acid ethyl ester*

10 LC/MS (m/z) 397.6 ( $M^+$ ); RT = 3.73, UV purity = 97.7, ELS purity = 99.8.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 1.50 (d, 3H); 4.10 (q, 2H); 4.35 (d, 1H); 4.50 (m, 1H); 6.15 (d, 2H); 7.00 (d, 2H); 7.50 (d, 1H); 8.15 (s, 1H); 8.55 (d, 1H); 9.72 (s, 1H).

*N-{4-[1-(3-Fluorophenylamino)methyl]-2-nitrophenyl}-2,2-dimethylpropionamide*

15  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (s, 9H); 4.30 (br m, 1H); 4.40 (d, 2H); 6.25 (d, 1H); 6.35 (d, 1H); 6.42 (br m, 1H); 7.08 (m, 1H); 7.65 (d, 1H); 8.20 (s, 1H); 8.80 (d, 1H); 10.70 (br s, 1H).

**Compounds of the invention**

20

**Example 1**

*1a {2-Amino-4-[1-(4-tert-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester*

*{4-[1-(4-tert-Butylphenylamino)-methyl]-2-nitrophenyl}-carbamic acid ethyl ester* (400 mg, 1.08 mmol) was dissolved in tetrahydrofuran (20 mL) and heated to 40 °C. Sodiumdithionite (1.13 g, 6.5 mmol) dissolved in water (20 mL) was added. The mixture was stirred vigorously at 40 °C until all starting material was consumed as judged by TLC. After cooling to ambient temperature brine (10 mL) is added and the mixture extracted with tetrahydrofuran (2x15 mL). The combined organic phases are dried over  $\text{MgSO}_4$ , filtered and evaporated to dryness *in vacuo*. Purified by chromatography using silica gel on a Flashmaster system eluting with heptane/ethyl acetate (linear gradient from 1:0 to 4:1). Fractions containing the product were pooled and evaporated *in vacuo* to yield the title compound as an off-white solid (230 mg, 62 %). LC/MS (m/z) 341.1 ( $M^+$ ); RT = 2.12, UV purity = 97.8, ELS purity = 99.1.  $^1\text{H}$

25

30

NMR (CDCl<sub>3</sub>): 1.27 (s, 9H); 1.32 (t, 3H); 3.75 (br, 2H, NH<sub>2</sub>); 3.80 (br s, 1H, NH); 4.22 (br m, 4H); 6.22 (br s, 1H, NH); 6.55 (d, 2H); 6.80 (m, 2H); 7.20 (br m, 3H).

The following compounds were prepared analogously:

5 *Ib* [2-Amino-4-phenylaminomethyl-phenyl]-carbamic acid ethyl ester

LC/MS (m/z) 285.1 (M<sup>+</sup>); RT = 1.46, UV purity = 98.2, ELS purity = 99.5. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.75 (br s, 2H, NH<sub>2</sub>); 3.95 (br s, 1H, NH); 4.22 (br m, 4H); 6.25 (br s, 1H, NH); 6.60 (d, 2H); 6.72 (t, 1H); 6.82 (m, 2H); 7.15 (t, 2H); 7.22 (br m, 1H).

10 *Ic* [2-Amino-4-(naphthalen-2-ylaminomethyl)-phenyl]-carbamic acid ethyl ester

LC/MS (m/z) 336.2 (MH<sup>+</sup>); RT = 2.20, UV purity = 98.2, ELS purity = 99.4. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.31 (t, 3H); 3.80 (br, 3H, NH<sub>2</sub>+NH); 4.25 (q, 2H); 4.35 (s, 2H); 6.25 (br s, 1H, NH); 6.82 (m, 3H); 6.92 (m, 1H); 7.18 (m, 1H); 7.22 (br m, 1H); 7.35 (m, 1H); 7.65 (br m, 3H).

15

*Id* [2-Amino-4-(p-tolylamino-methyl)-phenyl]-carbamic acid ethyl ester

LC/MS (m/z) 298.1 (M<sup>+</sup>); RT = 1.50, UV purity = 98.3, ELS purity = 98.4. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 2.22 (s, 3H); 3.78 (br, 3H, NH<sub>2</sub>+NH); 4.22 (br m, 4H); 6.25 (br s, 1H, NH); 6.55 (d, 2H); 6.80 (m, 2H); 6.98 (d, 2H); 7.21 (br m, 1H).

20

*Ie* {2-Amino-4-[(4-trifluoromethylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester

LC/MS (m/z) 353.1 (M<sup>+</sup>); RT = 2.58, UV purity = 97.9, ELS purity = 99.2. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.76 (br s, 2H, NH<sub>2</sub>); 4.23 (br m, 4H); 4.40 (br s, 1H, NH); 6.28 (br s, 1H, NH); 6.60 (d, 2H); 6.75 (m, 2H); 7.20 (br m, 1H); 7.40 (d, 2H).

25

*If* {2-Amino-4-[(4-chlorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester

LC/MS (m/z) 319.0 (MH<sup>+</sup>); RT = 2.24, UV purity = 98.9, ELS purity = 98.7. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.31 (t, 3H); 3.76 (br s, 2H, NH<sub>2</sub>); 4.00 (br s, 1H, NH); 4.22 (br m, 4H); 6.23 (br s, 1H, NH); 6.52 (d, 2H); 6.76 (m, 2H); 7.10 (d, 2H); 7.22 (br m, 1H).

30

*1g {2-Amino-4-[(3-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 303.1 ( $M^+$ ); RT = 2.08, UV purity = 98.5, ELS purity = 99.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.32 (t, 3H); 3.75 (br s, 2H, NH<sub>2</sub>); 4.15 (br s, 1H, NH); 4.24 (br m, 4H); 6.20 (br s, 1H, NH); 6.30 (m, 1H); 6.38 (m, 2H); 6.78 (m, 2H); 7.08 (m, 1H); 7.22 (br m, 1H).

*1h {2-Amino-4-[(4-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 304.2 ( $M^+$ ); RT = 1.58, UV purity = 96.1, ELS purity = 98.8.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.32 (t, 3H); 3.82 (br s, 3H, NH+NH<sub>2</sub>); 4.18 (s, 2H); 4.23 (q, 2H); 6.25 (br s, 1H, NH); 6.52 (m, 2H); 6.77 (m, 2H); 6.88 (m, 2H); 7.20 (br m, 1H).

*1i {2-Amino-4-[(2-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 303.0 ( $M^+$ ); RT = 2.16, UV purity = 99.5, ELS purity = 99.8.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.75 (br s, 2H, NH<sub>2</sub>); 4.21 (q, 2H); 4.28 (s, 2H); 4.38 (br s, 1H, NH); 6.30 (br s, 1H, NH); 6.63 (m, 2H); 6.70 (m, 2H); 6.95 (m, 2H); 7.20 (br m, 1H).

*1j [2-Amino-4-(biphenyl-4-ylaminomethyl)-phenyl]-carbamic acid ethyl ester*

LC/MS (m/z) 361.2 ( $M^+$ ); RT = 2.45, UV purity = 97.0, ELS purity = 98.3.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.32 (t, 3H); 3.90 (br s, 3H, NH+NH<sub>2</sub>); 4.21 (q, 2H); 4.30 (s, 2H); 6.25 (br s, 1H, NH); 6.70 (m, 2H); 6.82 (m, 2H); 7.25 (m, 2H); 7.37 (m, 2H); 7.44 (m, 2H); 7.55 (m, 2H).

*1k {2-Amino-4-[(2,4-difluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 320.1 ( $M^+$ ); RT = 2.24, UV purity = 95.9, ELS purity = 99.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.31 (t, 3H); 3.75 (br s, 2H, NH<sub>2</sub>); 4.12 (br s, 1H, NH); 4.23 (br m, 4H); 6.27 (br s, 1H, NH); 6.55 (m, 1H); 6.70 (m, 1H); 6.78 (m, 3H); 7.22 (br m, 1H).

*1l {2-Amino-4-[(4-methoxyphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester*

LC/MS (m/z) 314.9 ( $M^+$ ); RT = 1.29, UV purity = 95.6, ELS purity = 99.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.31 (t, 3H); 3.72 (br m, 6H, OCH<sub>3</sub>+NH+NH<sub>2</sub>); 4.18 (s, 2H); 4.24 (q, 2H); 6.30 (br s, 1H, NH); 6.60 (d, 2H); 6.78 (br m, 4H); 7.21 (br m, 1H).

**1m** {2-Amino-4-[(4-cyclohexylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester

LC/MS (m/z) 366.9 (MH<sup>+</sup>); RT = 2.45, UV purity = 96.2, ELS purity = 99.5. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.30 (br m, 9H); 1.82 (m, 4H); 2.40 (m, 1H); 3.78 (br, 3H, NH<sub>2</sub>+NH);  
5 4.22 (br m, 4H); 6.25 (br s, 1H, NH); 6.57 (d, 1H); 6.62 (d, 1H); 6.80 (m, 2H); 7.02 (m, 2H); 7.20 (br m, 1H).

**1n** [2-Amino-4-(indan-5-ylaminomethyl)-phenyl]-carbamic acid ethyl ester

LC/MS (m/z) 325.2 (MH<sup>+</sup>); RT = 1.75, UV purity = 96.1, ELS purity = 98.4. <sup>1</sup>H  
10 NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 2.02 (m, 2H); 2.80 (m, 4H); 3.75 (br, 3H, NH<sub>2</sub>+NH); 4.22 (br m, 4H); 6.27 (br s, 1H, NH); 6.42 (d, 1H); 6.55 (s, 1H); 6.80 (m, 2H); 7.00 (d, 1H); 7.21 (br m, 1H).

**1o** {2-Amino-4-[(4-isopropylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester

15 LC/MS (m/z) 326.2 (MH<sup>+</sup>); RT = 1.91, UV purity = 95.2, ELS purity = 98.5. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.20 (d, 6H), 1.32 (t, 3H); 2.80 (m, 1H); 3.75 (br, 3H, NH<sub>2</sub>+NH); 4.22 (br m, 4H); 6.25 (br s, 1H, NH); 6.57 (d, 2H); 6.81 (m, 2H); 7.05 (d, 2H); 7.20 (br m, 1H).

20 **1p** {2-Amino-4-[(4-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester

LC/MS (m/z) 340.2 (M<sup>+</sup>); RT = 2.16, UV purity = 97.2, ELS purity = 99.5. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.90 (t, 3H); 1.32 (m, 5H); 1.55 (m, 2H); 2.52 (t, 2H); 3.72 (br, 2H, NH<sub>2</sub>); 3.88 (br, 1H, NH); 4.21 (br m, 4H); 6.22 (br s, 1H, NH); 6.56 (d, 2H); 6.80 (m, 2H); 6.98 (d, 2H); 7.20 (br m, 1H).

25

## Example 2

**1q** {2-Amino-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester

A suspension of {4-[2-(4-Chloro-3-fluorophenyl)ethyl]-2-nitrophenyl}carbamic acid  
30 ethyl ester (1.80 g, 4.89 mmol), zinc (1.96 g, 29.4 mmol) and ammonium chloride (2.60, 48.9 mmol) was refluxed in methanol (50 mL) for 3 hours. The mixture was filtered off and purified by chromatography using silica gel on a Flashmaster system eluting with heptane/ethyl acetate (linear gradient from 1:0 to 5:1). Fractions

containing the product were pooled and evaporation *in vacuo* gave the title compound as an off-white solid (1.27 g, 77%).

LC/MS (m/z) 337.3 ( $M^+$ ); RT = 2.58, UV purity = 95.7, ELS purity = 98.3.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.80 (br, 2H); 4.20 (q, 2H); 4.35 (br m, 3H); 6.35 (br m, 3H);  
5 6.75 (m, 2H); 7.10 (m, 1H); 7.22 (m, 1H).

The following compounds were prepared analogously:

*Ir* {2-Amino-4-[(2,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester

10 LC/MS (m/z) 355.1 ( $M^+$ ); RT = 2.83, UV purity = 99.5, ELS purity = 99.7.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.31 (t, 3H); 3.77 (br s, 2H); 4.20 (q, 2H); 4.28 (br m, 2H); 4.68 (br t, 1H); 6.27 (br s, 1H); 6.50 (d, 1H); 6.75 (m, 2H); 7.05 (d, 1H); 7.22 (br m, 2H).

*Is* {2-Amino-4-[(2,3-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester

15 LC/MS (m/z) 355.0 ( $M^+$ ); RT = 2.79, UV purity = 95.9, ELS purity = 99.8.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.75 (br s, 2H); 4.20 (q, 2H); 4.30 (br m, 2H); 4.85 (br m, 1H); 6.30 (br s, 1H); 6.48 (d, 1H); 6.72-6.80 (m, 3H); 7.05 (m, 1H); 7.22 (br d, 1H).

*It* {2-Amino-4-[(3,5-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester

20 LC/MS (m/z) 354.9 ( $M^+$ ); RT = 2.85, UV purity = 98.5, ELS purity = 99.4.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.78 (br s, 2H); 4.15 (m, 2H); 4.25 (br m, 3H); 6.30 (br s, 1H); 6.45 (s, 2H); 6.65 (s, 1H); 6.75 (m, 2H); 7.22 (br d, 1H).

*Iu* {2-Amino-4-[(3,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester

25 LC/MS (m/z) 354.0 ( $M^+$ ); RT = 2.66, UV purity = 94.5, ELS purity = 99.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.75 (br s, 2H); 4.15 (br m, 3H); 4.22 (q, 2H); 6.27 (br s, 1H); 6.45 (d, 1H); 6.65 (s, 1H); 6.75 (m, 2H); 7.12 (d, 1H); 7.20 (br d, 1H).

*Iv* {2-Amino-4-[(3-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl  
30 ester

LC/MS (m/z) 353.1 ( $M^+$ ); RT = 2.66, UV purity = 98.8, ELS purity = 99.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.75 (br s, 2H); 4.18-4.28 (br m, 5H); 6.32 (br s, 1H); 6.70-6.80 (br m, 3H); 6.82 (s, 1H); 6.90 (d, 1H); 7.20 (br m, 2H).

*Ix* {2-Amino-4-[(3-fluoro-4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 371.1 ( $M^+$ ); RT = 2.74, UV purity = 95.2, ELS purity = 99.5.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.70 (br, 2H); 4.10 (m, 4H); 4.50 (br, 1H); 6.30 (br m, 3H);  
5 6.60 (m, 2H); 7.20 (m, 2H).

*Iy* {2-Amino-4-[(3,4-difluorophenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 321.1 ( $M^+$ ); RT = 2.24, UV purity = 95.3, ELS purity = 98.0.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.80 (br, 3H); 4.15 (s, 2H); 4.25 (q, 2H); 6.22 (m, 1H); 6.40 (br  
10 s, 1H); 6.45 (m, 1H); 6.72 (m, 2H); 6.90 (m, 1H); 7.20 (d, 1H).

*Iz* {2-Amino-4-[(4-cyanophenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 310.0 ( $M^+$ ); RT = 2.04, UV purity = 97.8, ELS purity = 99.3.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.75 (br, 2H); 4.20 (m, 4H); 4.65 (br, 1H); 6.35 (br, 1H); 6.55  
15 (d, 2H); 6.72 (d, 2H); 7.20 (m, 1H); 7.50 (m, 2H).

*Iaa* {2-Amino-4-[(4-fluoro-3-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 371.2 ( $M^+$ ); RT = 2.70, UV purity = 98.0, ELS purity = 98.8.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.90 (br, 3H); 4.15 (s, 2H); 4.25 (q, 2H); 6.40 (br s, 1H); 6.60  
20 (m, 1H); 6.75 (m, 3H); 6.95 (m, 1H); 7.20 (d, 1H).

*Iba* {2-Amino-4-[(3-chloro-4-methylphenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 334.0 ( $M^+$ ); RT = 2.49, UV purity = 97.0, ELS purity = 99.6.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 2.20 (s, 3H); 3.75 (br, 3H); 4.15 (s, 2H); 4.25 (q, 2H); 6.30 (br,  
25 1H); 6.40 (d, 1H); 6.65 (s, 1H); 6.72 (d, 2H); 6.98 (d, 1H); 7.20 (d, 1H).

*Ica* {2-Amino-4-[(3-chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 320.0 ( $M^+$ ); RT = 2.33, UV purity = 97.5, ELS purity = 99.7.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 3.75 (br, 3H); 4.15 (s, 2H); 4.20 (q, 2H); 6.40-6.50 (br, 2H);  
30 6.55 (s, 1H); 6.65-6.80 (br, 3H); 7.00 (m, 1H); 7.18 (d, 1H).

*1da* [2-Amino-4-(*m*-tolylaminomethyl)phenyl]carbamic acid ethyl ester

LC/MS (m/z) 298.1 ( $M^+$ ); RT = 1.66, UV purity = 95.0, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.30 (t, 3H); 2.22 (s, 3H); 3.75 (br, 3H); 4.20 (m, 4H); 6.40 (br, 3H); 6.50 (d, 1H); 6.72 (br, 2H); 7.00 (m, 1H); 7.15 (d, 1H).

5

*1ea* {2-Amino-4-[1-(4-chlorophenylamino)ethyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 333.5 ( $M^+$ ); RT = 2.37, UV purity = 98.1, ELS purity = 99.4.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.30 (t, 3H); 1.45 (d, 3H); 3.70 (br, 2H); 3.95 (br, 1H); 4.20 (q, 2H); 4.40 (q, 1H); 6.25 (br, 1H); 6.40 (d, 2H); 6.75 (m, 2H); 7.00 (d, 2H); 7.20 (d, 1H).

10

*1fa* {2-Amino-4-[1-(4-trifluoromethylphenylamino)ethyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 368.2 ( $M^+$ ); RT = 2.70, UV purity = 99.8, ELS purity = 97.7.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.20 (t, 3H); 1.40 (d, 3H); 4.05 (q, 2H); 4.30 (q, 1H); 4.80 (br, 2H); 6.55 (br, 3H); 6.63 (s, 1H); 6.80 (d, 1H); 7.10 (d, 1H); 7.30 (d, 2H); 8.45 (br, 1H).

15

*1cbN*-{2-Amino-4-[(3-fluorophenylamino)methyl]phenyl}-2,2-dimethylpropionamide

LC/MS (m/z) 316.5 ( $MH^+$ ); RT = 2.15, UV purity = 94.6, ELS purity = 99.7.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (s, 9H); 3.80 (br s, 2H); 4.15 (br s, 1H); 4.25 (br m, 2H); 6.28 (d, 1H); 6.40 (m, 2H); 6.78 (m, 2H); 7.08 (m, 1H); 7.15 (d, 1H); 7.30 (br s, 1H).

20

**Example 3***1ga* {4-[(4-Chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester

25 A solution of (4-formylphenyl)carbamic acid ethyl ester (0.50 g, 2.59 mmol) and 4-chloroaniline (0.43 g, 3.36 mmol) in dry ethanol (10 mL) was refluxed for 12 hours, cooled on an ice bath and the precipitated imine filtered off. It was washed once with cold water and suspended in methanol (10 mL) and acetic acid (1 mL). Sodium cyanoborohydride (0.42 g, 6.75 mmol) was added and the mixture stirred 1 hour at ambient temperature. A second portion of sodium cyanoborohydride (0.42 g, 6.75 mmol) was added and the mixture stirred 3 hours at ambient temperature. A saturated solution of sodium hydrogencarbonate (50 mL) was added and the precipitate filtered off and washed twice with water. Purified by chromatography using silica gel on a

30

Flashmaster system eluting with heptane/ethyl acetate (linear gradient from 1:0 to 5:1). Fractions containing the product were pooled and evaporation *in vacuo* gave the title compound as a white solid (0.50 g, 73%).

LC/MS (m/z) 305.8 (MH<sup>+</sup>); RT = 2.95, UV purity = 97.2, ELS purity = 99.5. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.35 (t, 3H); 4.05 (br s, 1H); 4.25 (br m, 4H); 6.60 (br m, 3H); 7.15 (d, 2H); 7.35 (br m, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 15.0, 48.3, 61.7, 114.3, 119.3, 122.5, 128.6, 129.5, 134.2, 137.6, 147.0, 154.0.

*1ha* {4-[(4-Trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 339.4 (MH<sup>+</sup>); RT = 3.45, UV purity = 97.2, ELS purity = 98.3. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.35 (t, 3H); 4.25 (q, 2H); 4.35 (br m, 3H); 6.55 (br s, 1H); 6.65 (d, 2H); 7.30-7.45 (br m, 6H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 14.9, 47.7, 61.7, 112.4, 119.4, 122.5, 127.0, 128.5, 134.2, 137.6, 150.8, 154.0.

*1ia* {4-[1-(4-Chlorophenylamino)ethyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 318.1 (M<sup>+</sup>); RT = 3.03, UV purity = 97.5, ELS purity = 98.1. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.28 (t, 3H); 1.47 (d, 3H); 4.00 (br, 1H); 4.20 (q, 2H); 4.40 (q, 1H); 6.40 (d, 2H); 6.55 (br, 1H); 7.00 (d, 2H); 7.20 (d, 2H); 7.33 (d, 2H).

*1ja* {4-[(4-Fluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester

LC/MS (m/z) 302.1 (M<sup>+</sup>); RT = 2.20, UV purity = 95.0, ELS purity = 97.3. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 2.25 (s, 3H); 4.0 (br s, 1H); 4.25 (br m, 4H); 6.35 (br s, 1H); 6.55 (br m, 2H); 6.87 (br m, 2H); 7.17 (br m, 2H); 7.75 (br d, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 14.6, 17.7, 48.6, 61.3, 113.8, 115.6, 126.1, 129.6, 135.1, 144.3, 156.9.

25

*1ka* {4-[(4-Chlorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester

LC/MS (m/z) 318.1 (M<sup>+</sup>); RT = 3.12, UV purity = 98.6, ELS purity = 99.8. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.30 (t, 3H); 2.25 (s, 3H); 4.10 (br s, 1H); 4.25 (br m, 4H); 6.35 (br s, 1H); 6.55 (d, 2H); 7.15 (br m, 4H); 7.75 (br d, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 14.6, 17.7, 48.1, 61.3, 114.1, 122.3, 126.0, 129.1, 129.5, 134.3, 135.2, 146.4, 153.9.

30

*1la* {2-Methyl-4-[(4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 352.5 ( $M^+$ ); RT = 3.45, UV purity = 96.7, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.30 (t, 3H); 2.25 (s, 3H); 4.25 (br m, 4H); 4.40 (br s, 1H); 6.35 (br s, 1H); 6.62 (d, 2H); 7.15 (br m, 2H); 7.45 (d, 2H); 7.75 (br d, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.6, 17.7, 47.5, 61.4, 112.1, 123.9, 126.0, 126.6, 129.5, 135.3, 150.3, 153.9.

5

*1ma* {4-[(3,4-Difluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester

LC/MS (m/z) 320.2 ( $M^+$ ); RT = 3.12, UV purity = 95.6, ELS purity = 99.1.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.30 (t, 3H); 2.25 (s, 3H); 4.00 (br s, 1H); 4.20 (br m, 4H); 6.20-6.35 (br m, 3H); 6.95 (m, 1H); 7.15 (br m, 2H); 7.75 (br d, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.6, 17.7, 48.3, 61.4, 101.5, 108.1, 117.4, 121.4, 126.0, 129.5, 129.9, 134.1, 135.3, 142.1, 144.9, 149.9, 153.9.

10

*1na* {4-[(3-Fluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester

LC/MS (m/z) 302.4 ( $M^+$ ); RT = 3.08, UV purity = 96.7, ELS purity = 98.0.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.30 (t, 3H); 2.25 (s, 3H); 4.25 (br m, 5H); 6.35 (br m, 4H); 7.00-7.20 (br m, 3H); 7.75 (br d, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 14.6, 17.7, 47.8, 61.3, 99.6, 104.1, 108.8, 121.4, 126.1, 129.6, 130.2, 130.3, 134.3, 135.2, 149.7, 153.9, 163.1, 165.0.

15

*1oa* {2-Chloro-4-[(4-chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 339.1 ( $M^+$ ); RT = 3.58, UV purity = 98.3, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 4.10 (br, 1H); 4.30 (br, 4H); 6.55 (d, 2H); 7.10 (br m, 3H); 7.22 (d, 1H); 7.40 (s, 1H); 8.15 (d, 1H).

20

*1pa* {2-Chloro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 372.3 ( $M^+$ ); RT = 3.74, UV purity = 96.5, ELS purity = 99.8.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.35 (t, 3H); 4.25 (q, 2H); 4.35 (s, 2H); 4.45 (br, 1H); 6.65 (d, 2H); 7.10 (br, 1H); 7.22 (d, 1H); 7.35 (s, 1H); 7.45 (d, 2H); 8.20 (d, 1H).

25

*1qa* {2-Chloro-4-[(4-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 323.1 ( $M^+$ ); RT = 2.91, UV purity = 99.7, ELS purity = 96.7.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.32 (t, 3H); 4.10 (br s, 1H); 4.25 (br m, 4H); 6.55 (m, 2H); 6.88 (m, 2H); 7.10 (br s, 1H); 7.22 (d, 1H); 7.47 (s, 1H); 8.15 (d, 1H).

30

*Ira* {2-Chloro-4-[(3-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 322.6 ( $M^+$ ); RT = 3.37, UV purity = 99.9, ELS purity = 99.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.33 (t, 3H); 4.00 (br s, 1H); 4.25 (br m, 4H); 6.28 (d, 1H); 6.40 (m, 2H);  
5 7.08 (m, 2H); 7.22 (d, 1H); 7.37 (s, 1H); 8.15 (d, 1H).

*Isa* {2-Chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 374.0 ( $M^+$ ); RT = 3.78, UV purity = 99.9, ELS purity = 97.6.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.35 (t, 3H); 4.15 (br s, 1H); 4.25 (br m, 4H); 6.45 (d, 1H); 6.70 (s, 1H);  
10 7.10 (br s, 1H); 7.15 (d, 1H); 7.20 (d, 1H); 7.35 (s, 1H); 8.15 (d, 1H).

*Ita* {2-Chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 358.0 ( $M^+$ ); RT = 3.62, UV purity = 99.9, ELS purity = 96.4.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.32 (t, 3H); 4.15 (br s, 1H); 4.25 (br m, 4H); 6.35 (m, 2H); 7.10 (m, 2H);  
15 7.22 (d, 1H); 7.35 (s, 1H); 8.15 (d, 1H).

*Iua* {4-[(4-Chlorophenylamino)methyl]-2-fluorophenyl}carbamic acid ethyl ester

LC/MS (m/z) 323.1 ( $M^+$ ); RT = 3.24, UV purity = 99.9, ELS purity = 99.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.32 (t, 3H); 4.15 (br s, 1H); 4.23 (br m, 4H); 6.50 (m, 2H); 6.78 (br s, 1H);  
20 7.10 (m, 4H); 8.05 (br m, 1H).

*Iva* {4-[(4-chloro-3-fluorophenylamino)methyl]-2-fluorophenyl}carbamic acid ethyl ester

LC/MS (m/z) 340.6 ( $M^+$ ); RT = 3.37, UV purity = 96.8, ELS purity = 99.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.32 (t, 3H); 4.10 (br s, 1H); 4.25 (br m, 4H); 6.35 (m, 2H); 6.75 (br s, 1H);  
25 7.10 (m, 3H); 8.07 (br m, 1H).

*Ixa* {2-Fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester

LC/MS (m/z) 356.2 ( $M^+$ ); RT = 3.45, UV purity = 97.1, ELS purity = 97.8.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.32 (t, 3H); 4.22 (q, 2H); 4.32 (s, 2H); 4.40 (s, 1H); 6.60 (d, 2H); 6.78 (br s, 1H);  
30 7.08 (m, 2H); 7.40 (d, 2H); 8.05 (br m, 1H).

**Iya** {4'-Dimethylamino-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl}carbamic acid ethyl ester

LC/MS (m/z) 408.0 ( $M^+$ ); RT = 2.49, UV purity = 97.9, ELS purity = 99.7.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.25 (t, 3H); 3.00 (s, 6H); 4.10 (br m, 1H); 4.17 (q, 2H); 4.28 (br s, 2H);  
5 6.30 (d, 1H); 6.38 (m, 2H); 6.75 (br s, 1H); 6.83 (d, 2H); 7.08 (m, 1H); 7.17 (s, 1H);  
7.22 (m, 2H); 7.30 (d, 1H); 8.10 (br m, 1H).

**Iza** {4'-Dimethylamino-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl}-carbamic acid ethyl ester

10 LC/MS (m/z) 458.0 ( $M^+$ ); RT = 3.09, UV purity = 97.2, ELS purity = 99.7.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.25 (t, 3H); 3.00 (s, 6H); 4.10 (br m, 1H); 4.17 (q, 2H); 4.28 (br s, 2H);  
6.38 (m, 2H); 6.62 (d, 2H); 6.75 (br s, 1H); 6.83 (d, 2H); 7.17 (s, 1H); 7.30 (d, 1H);  
7.40 (d, 2H); 8.10 (br m, 1H).

15 **Iab** {4'-Chloro-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl}carbamic acid ethyl ester

LC/MS (m/z) 397.4 ( $M^+$ ); RT = 4.22, UV purity = 97.3, ELS purity = 98.7.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.25 (t, 3H); 3.90 (br m, 1H); 4.15 (q, 2H); 4.35 (br s, 2H); 6.30 (d, 1H);  
6.36 (m, 2H); 6.50 (br s, 1H); 7.05 (m, 1H); 7.20 (s, 1H); 7.22 (s, 1H); 7.30 (d, 1H);  
20 7.40 (d, 1H); 7.50 (d, 2H); 8.10 (br m, 1H).

**Ibb** {4'-Chloro-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl}carbamic acid ethyl ester

LC/MS (m/z) 449.2 ( $M^+$ ); RT = 4.09, UV purity = 97.7, ELS purity = 91.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.27 (t, 3H); 3.95 (br m, 1H); 4.15 (q, 2H); 4.35 (br m, 2H); 6.47 (br s, 1H);  
25 6.62 (d, 2H); 7.15 (s, 1H); 7.28 (d, 2H); 7.35 (d, 1H); 7.40 (d, 2H); 7.48 (d, 2H); 8.10 (br m, 1H).

**Idb** N-{4-[(4-Chlorophenylamino)methyl]phenyl}butyramide

30 LC/MS (m/z) 303.3 ( $M^+$ ); RT = 2.73, UV purity = 96.6, ELS purity = 99.9.  $^1\text{H}$  NMR (CDCl<sub>3</sub>): 1.00 (t, 3H); 1.75 (m, 2H); 2.32 (t, 2H); 4.19 (br s, 1H); 4.25 (s, 2H); 6.55 (d, 2H); 7.05 (br s, sH); 7.10 (d, 2H); 7.30 (d, 2H); 7.50 (d, 2H).

**1eb** *N*-{4-[(3,4-Dichlorophenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 337.6 ( $M^+$ ); RT = 3.22, UV purity = 96.0, ELS purity = 99.6.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.00 (t, 3H); 1.77 (m, 2H); 2.32 (t, 2H); 4.10 (br s, 1H); 4.25 (s, 2H); 6.45 (d, 1H); 6.70 (s, 1H); 7.10 (br s, 1H); 7.15 (d, 1H); 7.30 (d, 2H); 7.50 (d, 2H).

5

**1fb** *N*-{4-[(4-Chloro-3-fluorophenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 320.9 ( $M^+$ ); RT = 3.08, UV purity = 96.9, ELS purity = 99.6.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.03 (t, 3H); 1.75 (m, 2H); 2.32 (t, 2H); 4.15 (br s, 1H); 4.22 (s, 2H); 6.32 (m, 1H); 6.40 (m, 1H); 7.10 (m, 2H); 7.30 (d, 2H); 7.55 (d, 2H).

10

**1gb** *N*-{4[(4-fluorophenylamino)methyl]-2-methylphenyl}butyramide

LC/MS (m/z) 300.6 ( $M^+$ ); RT = 1.89, UV purity = 99.5, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.78 (m, 2H); 2.22 (s, 3H); 2.38 (t, 2H); 4.00 (br, 1H); 4.20 (s, 2H); 6.55 (m, 2H); 6.90 (br m, 3H); 7.18 (m, 2H); 7.80 (d, 1H).

15

**1hb** *N*-{4[(3-fluorophenylamino)methyl]-2-methylphenyl}butyramide

LC/MS (m/z) 300.5 ( $M^+$ ); RT = 2.79, UV purity = 99.5, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.78 (m, 2H); 2.22 (s, 3H); 2.38 (t, 2H); 4.15 (br, 1H); 4.23 (s, 2H); 6.28 (m, 1H); 6.40 (m, 2H); 6.95 (br s, 1H); 7.10 (m, 1H); 7.18 (m, 2H); 7.80 (d, 1H).

20

**1ib** *N*-{4-[(4-chlorophenylamino)methyl]-2-methylphenyl}butyramide

LC/MS (m/z) 317.2 ( $M^+$ ); RT = 2.72, UV purity = 99.4, ELS purity = 94.8.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.78 (m, 2H); 2.25 (s, 3H); 2.40 (t, 2H); 4.00 (br, 1H); 4.23 (s, 2H); 6.55 (d, 2H); 6.90 (br s, 1H); 7.10 (d, 2H); 7.18 (d, 2H); 7.78 (d, 1H).

25

**1jb** *N*-{4-[(3,4-Dichlorophenylamino)methyl]-2-methylphenyl}butyramide

LC/MS (m/z) 351.6 ( $M^+$ ); RT = 3.28, UV purity = 98.4, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.00 (t, 3H); 1.75 (m, 2H); 2.23 (s, 3H); 2.38 (t, 2H); 4.00 (br, 1H); 4.20 (s, 2H); 6.45 (d, 1H); 6.70 (s, 1H); 6.95 (br s, 1H); 7.15 (m, 3H); 7.80 (d, 1H).

30

**1kb** *N*-{4-[(4-Chloro-3-fluorophenylamino)methyl]-2-methylphenyl}butyramide

LC/MS (m/z) 334.7 ( $M^+$ ); RT = 3.06, UV purity = 99.7, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.78 (m, 2H); 2.25 (s, 3H); 2.40 (t, 2H); 4.00 (br, 1H); 4.22 (s, 2H); 6.30 (m, 1H); 6.40 (m, 1H); 6.90 (br s, 1H); 7.10 (m, 1H); 7.15 (m, 2H); 7.80 (d, 1H).

**1lb** *N*-{2-Chloro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 370.9 ( $M^+$ ); RT = 3.37, UV purity = 99.4, ELS purity = 99.2.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.80 (m, 2H); 2.40 (t, 2H); 4.32 (s, 2H); 4.45 (br, 1H); 6.60 (d, 2H); 7.22 (d, 1H); 7.38 (s, 1H); 7.40 (d, 2H); 7.60 (br s, 1H); 8.40 (d, 1H).

**1mb** *N*-{2-Chloro-4-[(4-fluorophenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 320.9 ( $M^+$ ); RT = 2.66, UV purity = 94.8, ELS purity = 99.2.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.80 (m, 2H); 2.40 (t, 2H); 4.10 (br, 1H); 4.22 (s, 2H); 6.55 (m, 2H); 6.85 (m, 2H); 7.22 (d, 1H); 7.40 (s, 1H); 7.60 (br s, 1H); 8.45 (d, 1H).

**1nb** *N*-{2-Chloro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 321.0 ( $M^+$ ); RT = 3.03, UV purity = 99.01, ELS purity = 99.8.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.80 (m, 2H); 2.43 (t, 2H); 4.15 (br 1H); 4.28 (s, 2H); 6.28 (m, 1H); 6.40 (br m, 2H); 7.08 (m, 1H); 7.22 (d, 1H); 7.38 (s, 1H); 7.55 (br s, 1H); 8.48 (d, 1H).

**1ob** *N*-{2-Chloro-4-[(4-chlorophenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 337.8 ( $M^+$ ); RT = 3.11, UV purity = 99.4, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.80 (m, 2H); 2.40 (t, 2H); 4.10 (br, 1H); 4.30 (s, 2H); 6.50 (d, 2H); 7.10 (d, 2H); 7.22 (d, 1H); 7.38 (s, 1H); 7.60 (br s, 1H); 8.40 (d, 1H).

**1pb** *N*-{2-Chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 371.9 ( $M^+$ ); RT = 3.45, UV purity = 93.5, ELS purity = 95.7.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.80 (m, 2H); 2.40 (t, 2H); 4.12 (br, 1H); 4.23 (s, 2H); 6.40 (m, 1H); 6.65 (s, 1H); 7.17 (d, 1H); 7.22 (d, 1H); 7.35 (s, 1H); 7.60 (br s, 1H); 8.38 (d, 1H).

**1qb** *N*-{2-Chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 355.24 ( $M^+$ ); RT = 3.34, UV purity = 98.1, ELS purity = 99.5.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.05 (t, 3H); 1.80 (m, 2H); 2.42 (t, 2H); 4.25 (s, 2H); 4.35 (br, 1H); 6.35 (br m, 2H); 7.10 (m, 1H); 7.22 (d, 1H); 7.35 (s, 1H); 7.60 (br s, 1H); 8.35 (d, 1H).

5

**1rb** *N*-{2-Fluoro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 305.0 ( $M^+$ ); RT = 2.97, UV purity = 99.4, ELS purity = 99.6.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.00 (t, 3H); 1.75 (m, 2H); 2.40 (t, 2H); 4.15 (br, 1H); 4.30 (s, 2H); 6.27 (d, 1H); 6.40 (br m, 2H); 7.10 (br m, 3H); 7.30 (br s, 1H); 8.30 (m, 1H).

10

**1sb** *N*-{4-[(4-Chlorophenylamino)methyl]-2-fluorophenyl}butyramide

LC/MS (m/z) 320.0 ( $M^+$ ); RT = 2.94, UV purity = 99.4, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.00 (t, 3H); 1.80 (m, 2H); 2.40 (t, 2H); 4.15 (br, 1H); 4.30 (s, 2H); 6.50 (d, 2H); 7.10 (br m, 4H); 7.30 (br s, 1H); 8.30 (m, 1H).

15

**1tb** *N*-{2-Fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide

LC/MS (m/z) 354.0 ( $M^+$ ); RT = 3.20, UV purity = 99.6, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.00 (t, 3H); 1.78 (m, 2H); 2.40 (t, 2H); 4.15 (br, 1H); 4.35 (s, 2H); 6.60 (d, 2H); 7.10 (m, 2H); 7.30 (br s, 1H); 7.40 (d, 2H); 8.30 (m, 1H).

20

**1ub** *N*-{4-[(3,4-Dichlorophenylamino)methyl]-2-fluorophenyl}butyramide

LC/MS (m/z) 355.0 ( $M^+$ ); RT = 3.29, UV purity = 99.7, ELS purity = 99.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.00 (t, 3H); 1.78 (m, 2H); 2.40 (t, 2H); 4.20 (br, 1H); 4.28 (s, 2H); 6.42 (d, 1H); 6.65 (s, 1H); 7.05 (m, 2H); 7.18 (d, 1H); 7.30 (br s, 1H); 8.30 (m, 1H).

25

**1vb** *N*-{4-[(4-Chloro-3-fluorophenylamino)methyl]-2-fluorophenyl}butyramide

LC/MS (m/z) 339.0 ( $M^+$ ); RT = 3.14, UV purity = 99.4, ELS purity = 97.9.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.00 (t, 3H); 1.75 (m, 2H); 2.40 (t, 2H); 4.00 (br, 1H); 4.25 (s, 2H); 6.30 (br m, 2H); 7.05 (br m, 3H); 7.30 (br s, 1H); 8.30 (m, 1H).

30

In vitro and in vivo testing

The compounds of the invention have been tested and shown effect in one or more of the below models:

5 **Relative efflux through the KCNQ2 channel.**

This exemplifies a KCNQ2 screening protocol for evaluating compounds of the present invention. The assay measures the relative efflux through the KCNQ2 channel, and was carried out according to a method described by Tang et al. (Tang, W. et. al., *J. Biomol. Screen.* **2001**, 6, 325-331) for hERG potassium channels with the  
10 modifications described below.

An adequate number of CHO cells stably expressing voltage-gated KCNQ2 channels were plated at a density sufficient to yield a mono-confluent layer on the day of the experiment. Cells were seeded on the day before the experiment and loaded with 1  
15  $\mu\text{Ci/ml}$  [ $^{86}\text{Rb}$ ] over night. On the day of the experiment, cells were washed with a HBSS-containing buffer. Cells were pre-incubated with drug for 30 min and the  $^{86}\text{Rb}^+$  efflux was stimulated by a submaximal concentration of 15 mM KCl in the continued presence of drug for additional 30 min. After a suitable incubation period, the supernatant was removed and counted in a liquid scintillation counter (Tricarb). Cells  
20 were lysed with 2 mM NaOH and the amount of  $^{86}\text{Rb}^+$  was counted. The relative efflux was calculated  $((\text{CPM}_{\text{super}}/(\text{CPM}_{\text{super}} + \text{CPM}_{\text{cell}}))_{\text{Cmpd}}/(\text{CPM}_{\text{super}}/(\text{CPM}_{\text{super}} + \text{CPM}_{\text{cell}}))_{15\text{mM KCl}})*100-100$ .

The compounds of the invention have an  $\text{EC}_{50}$  of less than 20000nM, in most cases  
25 less than 2000nM and in many cases less than 200nM. Accordingly, the compounds of the invention are considered to be useful in the treatment of diseases associated with the KCNQ family potassium channels.

**Electrophysiological patch-clamp recordings.**

30 Voltage-activated KCNQ2 currents were recorded from mammalian CHO cells by use of conventional patch-clamp recordings techniques in the whole-cell patch-clamp configuration (Hamill OP et.al. *Pflügers Arch* **1981**; 391: 85-100). CHO cells with stable expression of voltage-activated KCNQ2 channels were grown under normal

cell culture conditions in CO<sub>2</sub> incubators and used for electrophysiological recordings 1-7 days after plating. KCNQ2 potassium channels were activated by voltage steps up to + 80 mV in increments of 5-20 mV (or with a ramp protocol) from a membrane holding potential between – 100 mV and – 40 mV (Tatulian L et al. *J Neuroscience* 5 **2001**; 21 (15): 5535-5545). The electrophysiological effects induced by the compounds were evaluated on various parameters of the voltage-activated KCNQ2 current. Especially effects on the activation threshold for the current and on the maximum induced current were studied.

10 Some of the compounds of the invention have been tested in this test. A left-ward shift of the activation threshold or an increase in the maximum induced potassium current is expected to decrease the activity in neuronal networks and thus make the compounds useful in diseases with increased neuronal activity - like epilepsy.

#### 15 **Maximum electroshock**

The test was conducted in groups of male mice using corneal electrodes and administering a square wave current of 26mA for 0.4seconds in order to induce a convulsion characterised by a tonic hind limb extension (Wlaz et al. *Epilepsy Research* **1998**, 30, 219-229).

20

#### **Pilocarpine induced seizures**

Pilocarpine induced seizures are induced by intraperitoneal injection of pilocarpine 250mg/kg to groups of male mice and observing for seizure activity resulting in loss of posture within a period of 30 minutes (Starr et al. *Pharmacology Biochemistry and Behavior* **1993**, 45, 321-325)

25

#### **Electrical seizure -threshold test**

A modification of the up-and-down method (Kimball et a., *Radiation Research* 1957, 1-12) was used to determine the median threshold to induce tonic hind-limb extension in response to corneal electroshock in groups of male mice. The first mouse of each group received an electroshock at 14 mA, (0.4 s, 50 Hz) and was observed for seizure activity. If a seizure was observed the current was reduced by 1mA for the next

30

mouse, however, if no seizure was observed then the current was increased by 1mA. This procedure was repeated for all 15 mice in the treatment group.

#### **Chemical seizure -threshold threshold test**

- 5 The threshold dose of pentylenetetrazole required to induce a clonic convulsion was measured by timed infusion of pentylenetetrazole (5mg/ml at 0.5 ml/min) into a lateral tail vein of groups of male mice (Nutt et al. *J Pharmacy and Pharmacology* 1986, 38, 697-698).

#### 10 **Amygdala kindling**

- Rats underwent surgery to implantation of tri-polar electrodes into the dorsolateral amygdala. After surgery the animals were allowed to recover before the groups of rats received either varying doses of test compound or the drug's vehicle. The animals were stimulated with their initial after discharge threshold + 25  $\mu$ A daily for 3-5 weeks and on each occasion seizure severity, seizure duration, and duration of electrical after discharge were noted. (Racine. *Electroencephalography and Clinical Neurophysiology* 1972, 32, 281-294).

#### **Side effects**


- 20 Central nervous system side effects were measured by measuring the time mice would remain on rotarod apparatus (Capacio et al. *Drug and Chemical Toxicology* 1992, 15, 177-201); or by measuring their locomotor activity by counting the number of infra-red beams crossed in a test cage ((Watson et al. *Neuropharmacology* 1997, 36, 1369-1375). Hypothermic actions on the animals core body temperature of the compound were measured by either rectal probe or implanted radiotelemetry transmitters capable of measuring temperature (Keeney et al. *Physiology and Behaviour* 2001, 74, 177-184).

#### 30 **Pharmacokinetics**

The pharmacokinetic properties of the compound were determined via. i.v. and p.o. dosing to Sprague Dawley rats, and, thereafter, drawing blood samples over 20 hours. Plasma concentrations were determined with LC/MS/MS.

**Claims**

1. A substituted aniline derivative of formula I



5

wherein

**U** is O, S or  $\text{NR}^{2'}$ ;

10 **s** is 0 or 1;

**X** is CO or  $\text{SO}_2$ ;

15 **Z** is O, S or  $\text{NR}^4$ , wherein  $\text{R}^4$  is selected from the group consisting of hydrogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl- $\text{C}_{1-6}$ -alk(en/yn)yl, hydroxy- $\text{C}_{1-6}$ -alk(en/yn)yl and hydroxy- $\text{C}_{3-8}$ -cycloalk(en)yl;

**q** is 0 or 1;

20  $\text{R}^1$  and  $\text{R}^{1'}$  are independently selected from the group consisting of hydrogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl- $\text{C}_{1-6}$ -alk(en/yn)yl, acyl, hydroxy- $\text{C}_{1-6}$ -alk(en/yn)yl, hydroxy- $\text{C}_{3-8}$ -cycloalk(en)yl, halo- $\text{C}_{1-6}$ -alk(en/yn)yl and halo- $\text{C}_{3-8}$ -cycloalk(en)yl;

25  $\text{R}^2$  is selected from the group consisting of hydrogen, halogen,  $\text{C}_{1-6}$ -alk(en/yn)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl,  $\text{C}_{3-8}$ -cycloalk(en)yl- $\text{C}_{1-6}$ -alk(en/yn)yl, Ar, Ar- $\text{C}_{1-6}$ -alk(en/yn)yl, Ar- $\text{C}_{3-8}$ -cycloalk(en)yl, acyl, hydroxy- $\text{C}_{1-6}$ -alk(en/yn)yl, hydroxy-

C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl and cyano;  
provided that when **R**<sup>2</sup> is halogen or cyano, then **s** is 0;

5 when **s** is 1 and **U** is **NR**<sup>2'</sup> then **R**<sup>2'</sup> is selected from the group consisting of  
hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-  
alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-  
alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-  
cycloalk(en)yl; or **R**<sup>2</sup> and **R**<sup>2'</sup> together form a 5-8 membered saturated or  
unsaturated ring which optionally contains one further heteroatom;

10


**R**<sup>3</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl,  
C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-  
cycloalk(en)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-  
alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;

15


and

**Y** represents a group of formulae **VI**, **VII**, **VIII**, **IX** or **XXX**:


87




VI




VII



VIII



IX



XXX

wherein

5

the line represents a bond attaching the group represented by Y to the nitrogen atom;

W is O or S;

10

a is 0, 1, 2 or 3;

b is 0, 1, 2, 3 or 4;

15

c is 0 or 1;

d is 0, 1, 2 or 3;

**e** is 0, 1 or 2;

**f** is 0, 1, 2, 3, 4 or 5;

5 **g** is 0, 1, 2, 3 or 4;

**h** is 0, 1, 2 or 3; and

10 each **R**<sup>5</sup> is independently selected from the group consisting of a C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl, acyl, C<sub>1-6</sub>-alk(an/en/yn)yl, halo, halo-C<sub>1-6</sub>-alk(en/yn)yl, -CO-NR<sup>6</sup>R<sup>6'</sup>, cyano, nitro, -NR<sup>7</sup>R<sup>7'</sup>, -S-R<sup>8</sup>, -SO<sub>2</sub>R<sup>8</sup> and SO<sub>2</sub>OR<sup>8</sup>, or two substituents together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms;

15 **R**<sup>6</sup> and **R**<sup>6'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl and Ar;

20 **R**<sup>7</sup> and **R**<sup>7'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and acyl; and

25 **R**<sup>8</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and -NR<sup>9</sup>R<sup>9'</sup>; wherein **R**<sup>9</sup> and **R**<sup>9'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; with the provisos that when **R**<sup>5</sup> is SO<sub>2</sub>OR<sup>8</sup> then **R**<sup>8</sup> is not -NR<sup>9</sup>R<sup>9'</sup> and when **R**<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>, then **R**<sup>8</sup> is not a hydrogen atom;

30 or salts thereof;

with the proviso that the compound of formula I is not:

N-[4-[(4-aminophenyl)amino]methyl]phenyl]-acetamide;

N-[4-[(4-amino-2-methylphenyl)amino]methyl]phenyl]-acetamide;

N-[4-[[[(4-amino-3-methylphenyl)amino]methyl]phenyl]-acetamide;  
 2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)-  
 benzamide;  
 N-[4-[[[(3,4,5-trimethoxyphenyl)amino]methyl]phenyl]-acetamide;  
 5 N-[4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-  
 naphthalenyl)amino]methyl]phenyl]-acetamide;  
 N-[4-[[[3-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;  
 N-[4-[[[2-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]-acetamide;  
 N-[4-[[[(4-amino-3,5-dichlorophenyl)amino]methyl]phenyl]- acetamide;  
 10 N-[4-[[[(2,4-diamino-6-quinazoliny]amino]methyl]phenyl]- acetamide; or  
 N-[4-[[[(2,4-diamino-6-quinazoliny]amino]methyl]phenyl]- acetamide.

2. A compound according to Claim 1, wherein  $R^1$  and  $R^{1'}$  are independently  
 selected from the group consisting of hydrogen and  $C_{1-6}$ -alk(en/yn)yl.  
 15
3. A compound according to Claim 2, wherein at least one of  $R^1$  and  $R^{1'}$  is a  
 hydrogen atom.
4. A compound according to any one of Claims 1-3, wherein  $s$  is 1.  
 20
5. A compound according to any one of Claims 1-3, wherein  $s$  is 0.
6. A compound according to any one of Claims 4-5, wherein  $R^2$  is selected from the  
 group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl, Ar and halogen, provided that  
 25 when  $R^2$  is halogen, then  $s$  is 0.
7. A compound according to Claim 4, wherein  $U$  is  $NR^{2'}$  and at least one of  $R^2$  and  
 $R^{2'}$  is a hydrogen atom.
- 30 8. A compound according to Claim 7, wherein both  $R^2$  and  $R^{2'}$  are hydrogen atoms.
9. A compound according to any one of Claims 1-8, wherein  $X$  is CO.


10. A compound according to any one of Claims 1-9, wherein **q** is 0.
11. A compound according to any one of Claims 1-9, wherein **q** is 1.
- 5 12. A compound according to Claim 11, wherein **Z** is an oxygen atom.
13. A compound according to any one of Claims 1-12, wherein **R<sup>3</sup>** is C<sub>1-6</sub>-alk(en/yn)yl.
- 10 14. A compound according to any one of Claims 1-13 wherein **Y** represents a group of formulae **IX** or **XXX**.
15. A compound according to any one of Claims 1-14, wherein each **R<sup>5</sup>** is independently selected from the group consisting of a C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, cyano, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl and C<sub>1-6</sub>-alk(an/en/yn)oxy or two adjacent substituents together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms.
16. A compound according to any one of Claims 1-15, said compound being selected from the group consisting of:
  - {2-Amino-4-[(4-tert-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*
  - (2-Amino-4-phenylaminomethyl-phenyl)-carbamic acid ethyl ester;*
  - [2-Amino-4-(naphthalen-2-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;*
  - 25 *[2-Amino-4-(p-tolylamino-methyl)-phenyl]-carbamic acid ethyl ester;*
  - {2-Amino-4-[(4-trifluoromethylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*
  - {2-Amino-4-[(4-chlorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*
  - {2-Amino-4-[(3-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*
  - 30 *{2-Amino-4-[(4-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*
  - {2-Amino-4-[(2-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*
  - [2-Amino-4-(biphenyl-4-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;*

- {2-Amino-4-[(2,4-difluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-methoxyphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
5 *{2-Amino-4-[(4-cyclohexylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*[2-Amino-4-(indan-5-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-isopropylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
10 *{2-Amino-4-[(4-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(2,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(2,3-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
15 *{2-Amino-4-[(3,5-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(3,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(3-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(3-fluoro-4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
20 *{2-Amino-4-[(3,4-difluorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-cyanophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(4-fluoro-3-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
25 *{2-Amino-4-[(3-chloro-4-methylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Amino-4-[(3-chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*[2-Amino-4-(m-tolylaminomethyl)phenyl]carbamic acid ethyl ester;*  
*{2-Amino-4-[1-(4-chlorophenylamino)ethyl]phenyl}carbamic acid ethyl ester;*  
30 *{2-Amino-4-[1-(4-trifluoromethylphenylamino)ethyl]phenyl}carbamic acid ethyl ester;*  
*N-{2-Amino-4-[(3-fluorophenylamino)methyl]phenyl}-2,2-dimethylpropionamide;*  
*{4-[(4-Chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*

- {4-[(4-Trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{4-[1-(4-Chlorophenylamino)ethyl]phenyl}carbamic acid ethyl ester;*  
*{4-[(4-Fluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester;*  
*{4-[(4-Chlorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester;*  
5 *{2-Methyl-4-[(4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{4-[(3,4-Difluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester;*  
*{4-[(3-Fluorophenylamino)methyl]-2-methylphenyl}carbamic acid ethyl ester;*  
*{2-Chloro-4-[(4-chlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
10 *{2-Chloro-4-[(4-trifluoromethyl-phenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;*  
*{2-Chloro-4-[(4-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Chloro-4-[(3-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{2-Chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
15 *{2-Chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{4-[(4-Chlorophenylamino)methyl]-2-fluorophenyl}carbamic acid ethyl ester;*  
*{4-[(4-Chloro-3-fluorophenylamino)methyl]-2-fluorophenyl}carbamic acid ethyl ester;*  
20 *{2-Fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}carbamic acid ethyl ester;*  
*{4'-Dimethylamino-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl}carbamic acid ethyl ester;*  
*{4'-Dimethylamino-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl}carbamic acid ethyl ester;*  
25 *{4'-Chloro-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl}carbamic acid ethyl ester;*  
*{4'-Chloro-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl}carbamic acid ethyl ester;*  
*N-{4-[(4-chlorophenylamino)methyl]phenyl}butyramide;*  
30 *N-{4-[(3,4-dichlorophenylamino)methyl]phenyl}butyramide;*  
*N-{4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}butyramide;*  
*N-{4[(4-fluoro-phenylamino)methyl]-2-methylphenyl}butyramide;*  
*N-{4[(3-fluorophenylamino)methyl]-2-methylphenyl}butyramide;*

- N*-{4-[(4-chlorophenylamino)methyl]-2-methylphenyl}butyramide;  
*N*-{4-[(3,4-dichlorophenylamino)methyl]-2-methylphenyl}butyramide;  
*N*-{4-[(4-chloro-3-fluorophenylamino)methyl]-2-methylphenyl}butyramide;  
*N*-{2-chloro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide;  
5 *N*-{2-chloro-4-[(4-fluorophenylamino)methyl]phenyl}butyramide;  
*N*-{2-chloro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide;  
*N*-{2-chloro-4-[(4-chlorophenylamino)methyl]phenyl}butyramide;  
*N*-{2-chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl}butyramide;  
*N*-{2-chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}butyramide;  
10 *N*-{2-fluoro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide;  
*N*-{4-[(4-chlorophenylamino)methyl]-2-fluorophenyl}butyramide;  
*N*-{2-fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide;  
*N*-{4-[(3,4-dichlorophenylamino)methyl]-2-fluorophenyl}butyramide; and  
*N*-{4-[(4-chloro-3-fluorophenylamino)methyl]-2-fluorophenyl}butyramide.  
15 or a salt thereof.

17. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or diluents and a compound of the below formula I



wherein

U is O, S or NR<sup>2'</sup>;

**s** is 0 or 1;

**X** is CO or SO<sub>2</sub>;

5 **Z** is O, S or NR<sup>4</sup>, wherein **R**<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl and hydroxy-C<sub>3-8</sub>-cycloalk(en)yl;

**q** is 0 or 1;

10

**R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;

15

**R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl and cyano; provided that when **R**<sup>2</sup> is halogen or cyano then **s** is 0;

20

when **s** is 1 and **U** is NR<sup>2'</sup> then **R**<sup>2'</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl; or **R**<sup>2</sup> and **R**<sup>2'</sup> together form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;


25

**R**<sup>3</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;


30

and


Y represents a group of formulae VI, VII, VIII, IX or XXX:




VI




VII



VIII



IX



XXX

5

wherein

10 the line represents a bond attaching the group represented by Y to the nitrogen atom;

W is O or S;

15 a is 0, 1, 2 or 3;

**b** is 0, 1, 2, 3 or 4;

**c** is 0 or 1;

**d** is 0, 1, 2 or 3;

5

**e** is 0, 1 or 2;

**f** is 0, 1, 2, 3, 4 or 5;

10

**g** is 0, 1, 2, 3 or 4;

**h** is 0, 1, 2 or 3; and

15

each **R**<sup>5</sup> is independently selected from the group consisting of a C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl, acyl, C<sub>1-6</sub>-alk(an/en/yn)yl, halo, halo-C<sub>1-6</sub>-alk(en/yn)yl, -CO-NR<sup>6</sup>R<sup>6'</sup>, cyano, nitro, -NR<sup>7</sup>R<sup>7'</sup>, -S-R<sup>8</sup>, -SO<sub>2</sub>R<sup>8</sup> and SO<sub>2</sub>OR<sup>8</sup>, or two substituents together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms;

20

**R**<sup>6</sup> and **R**<sup>6'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl and Ar;

25

**R**<sup>7</sup> and **R**<sup>7'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and acyl; and

30

**R**<sup>8</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and -NR<sup>9</sup>R<sup>9'</sup>; wherein **R**<sup>9</sup> and **R**<sup>9'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; with the provisos that when **R**<sup>5</sup> is SO<sub>2</sub>OR<sup>8</sup> then **R**<sup>8</sup> is not -NR<sup>9</sup>R<sup>9'</sup> and when **R**<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>, then **R**<sup>8</sup> is not a hydrogen atom;

or salts thereof;

with the proviso that the compound of formula I is not:

5 2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)-benzamide;

N-[4-[[[(3,4,5-trimethoxyphenyl)amino]methyl]phenyl]-acetamide;

N-[4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]methyl]phenyl]-acetamide;

10 N-[4-[[[3-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[[2-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]-acetamide;


N-[4-[[[4-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[[(4-amino-3,5-dichlorophenyl)amino]methyl]phenyl]- acetamide;

N-[4-[[[(2,4-diamino-6-quinazoliny)amino]methyl]phenyl]- acetamide; or

15 N-[4-[[[(2,4-diamino-6-quinazoliny)amino]methyl]phenyl]- acetamide.

18. Use of a pharmaceutical composition one or more pharmaceutically acceptable carriers or diluents and a compound of the below formula **I**



20

wherein

25 U is O, S or NR<sup>2'</sup>;

s is 0 or 1;

**X** is CO or SO<sub>2</sub>;

**Z** is O, S or NR<sup>4</sup>, wherein **R**<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl and hydroxy-C<sub>3-8</sub>-cycloalk(en)yl;

**q** is 0 or 1;

**R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;






**R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl and cyano; provided that when **R**<sup>2</sup> is halogen or cyano then **s** is 0;

when **s** is 1 and **U** is NR<sup>2'</sup> then **R**<sup>2'</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl; or **R**<sup>2</sup> and **R**<sup>2'</sup> together form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;

**R**<sup>3</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;

and

**Y** represents a group of formulae **VI**, **VII**, **VIII**, **IX** or **XXX**:

**VI****VII****VIII****IX****XXX**

5

wherein

the line represents a bond attaching the group represented by **Y** to the nitrogen atom;

10

**W** is O or S;

**a** is 0, 1, 2 or 3;

15

**b** is 0, 1, 2, 3 or 4;

**c** is 0 or 1;

**d** is 0, 1, 2 or 3;

5 **e** is 0, 1 or 2;

**f** is 0, 1, 2, 3, 4 or 5;

**g** is 0, 1, 2, 3 or 4;

10

**h** is 0, 1, 2 or 3; and

each **R**<sup>5</sup> is independently selected from the group consisting of a C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl, acyl, C<sub>1-6</sub>-alk(an/en/yn)yl oxy, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl, 15 -CO-NR<sup>6</sup>R<sup>6'</sup>, cyano, nitro, -NR<sup>7</sup>R<sup>7'</sup>, -S-R<sup>8</sup>, -SO<sub>2</sub>R<sup>8</sup> and SO<sub>2</sub>OR<sup>8</sup>, or two substituents together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms;

20 **R**<sup>6</sup> and **R**<sup>6'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl and Ar;

**R**<sup>7</sup> and **R**<sup>7'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and 25 acyl; and

**R**<sup>8</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and -NR<sup>9</sup>R<sup>9'</sup>; wherein **R**<sup>9</sup> and **R**<sup>9'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; with 30 the provisos that when **R**<sup>5</sup> is SO<sub>2</sub>OR<sup>8</sup> then **R**<sup>8</sup> is not -NR<sup>9</sup>R<sup>9'</sup> and when **R**<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>, then **R**<sup>8</sup> is not a hydrogen atom;

or salts thereof

for increasing ion flow in a potassium channel of a mammal such as a human.

- 5 19. Use according to Claim 18 for the prevention, treatment or inhibition of a disorder or condition being responsive to an increased ion flow in a potassium channel, such disorder or condition is preferably a disorder or condition of the central nervous system.
- 10 20. Use according to claim 19 characterized in that the disorder or condition is selected from the group consisting of seizure disorders such as convulsions, epilepsy and status epilepticus.
- 15 21. Use according to claim 19 characterized in that the disorder or condition is selected from the group consisting of neuropathic and migraine pain disorders such as allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.
- 20 22. Use according to claim 19 characterized in that the disorder or condition is selected from the group consisting of anxiety disorders such as anxiety, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia, specific phobias, anxiety disorder due to general medical condition and substance-induced anxiety disorder.
- 25 23 Use according to claim 19 characterized in that the disorder or condition is selected from the group consisting of and neurodegenerative disorders such as Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced encephalopathy and other infection-related encephalopathies being caused by rubella viruses, herpes viruses, borrelia and by unknown pathogens, Creutzfeld-Jakob disease, Parkinson's disease, trauma-induced neurodegenerations.
- 30

24. Use according to claim 19 characterized in that the disorder or condition is selected from the group consisting of neuronal hyperexcitation states such as in medicament withdrawal or by intoxication.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK2004/000162

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C271/28 C07C233/43 A61P25/08 A61K31/167 A61K31/325

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                       | Relevant to claim No.         |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| P,X        | EP 1 369 420 A (AVENTIS PHARMA DEUTSCHLAND G.M.B.H., GERMANY; AJINOMOTO CO., INC.)<br>10 December 2003 (2003-12-10)<br>see paragraph '0095! on page 18<br>-----          | 1-3,5,6,<br>9,10,14,<br>15,17 |
| A          | WO 02/18318 A (WELLA AKTIENGESELLSCHAFT, GERMANY) 7 March 2002 (2002-03-07)<br>Claims 1, 5 and page 5, lines 14-15; page 15, paragraph c; page 21, paragraph n,<br>----- | 1-24                          |
| A          | WO 00/39118 A (ELI LILLY AND CO., USA; KYLE, JEFFREY, ALAN; ET AL.)<br>6 July 2000 (2000-07-06)<br>example 94<br>-----                                                   | 1-3,5,6,<br>9,10,13,<br>14,17 |
| A          | EP 0 515 684 A (CHUGAI PHARMACEUTICAL CO., LTD., JAPAN) 2 December 1992 (1992-12-02)<br>see compound 62 (page 44)<br>-----                                               | 1-24                          |
|            | -/--                                                                                                                                                                     |                               |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

2 July 2004

Date of mailing of the international search report

20/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5816 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Bueno Torres, M

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK2004/000162

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                               |
|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| Category *                                           | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                                                                                                                                                                       | Relevant to claim No.         |
| X                                                    | EP 0 386 452 A (BASF A.-G., GERMANY)<br>12 September 1990 (1990-09-12)<br><br>see compounds 72 and 116<br>-----                                                                                                                                                                                                                                                                                                                                                                                                          | 1-3,5,6,<br>9,10,<br>13-15,17 |
| A                                                    | PORRETTA, GIULIO CESARE ET AL: "Research on antibacterial and antifungal agents. II. Synthesis and antifungal activity of new (1H-imidazol-1-ylmethyl)benzenamine derivatives"<br>EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 23, no. 4, 1988, pages 311-317, XP002286080<br>compound 11e (page 315)<br>-----                                                                                                                                                                                                          | 1-24                          |
| X                                                    | DATABASE CHEMABS 'Online!<br>CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;<br>SCALZO, M. ET AL: "Studies on substances with antibacterial and antifungal activity. I. Synthesis and microbiological activity of imidazolylmethylaniline derivatives"<br>XP002286084<br>retrieved from STN<br>Database accession no. 1986:221893<br>RN: 102432-72-4 and 102432-79-1<br>abstract<br>& FARMACO, EDIZIONE SCIENTIFICA, vol. 41, no. 4, 1986, pages 292-307, XP009032497<br>compounds XX (f) and XXII (f) page 297<br>----- | 1-3,5,6,<br>9,10,13,<br>14    |
| A                                                    | MEYER, WALTER E. ET AL:<br>"N2-(4-Substituted-2,6-dichlorophenyl)-N1, N1-dimethylformamides as antihypertensive and diuretic agents"<br>JOURNAL OF MEDICINAL CHEMISTRY, vol. 27, no. 12, 1984, pages 1705-1710, XP002286081<br>compound 8c, Table IV, page 1709<br>-----                                                                                                                                                                                                                                                 | 1-24                          |
| A                                                    | DAVOLL, JOHN ET AL: "Antimalarial drugs. 24. Folate antagonists. 2. 2,4-Diamino-6-{aralkyl and (heterocyclic)methylamino}quinazolines, a novel class of antimetabolites of interest in drug-resistant malaria and Chagas' disease"<br>JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 8, 1972, pages 812-826, XP002286082<br>compound 38, Table II, page 814<br>-----<br><br>-/--                                                                                                                                           | 1-24                          |

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK2004/000162

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |                                                                                                                                                                                                                                                                 |                       |
|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Category °                                           | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                              | Relevant to claim No. |
| X                                                    | WO 01/09612 A (DRESDEN ARZNEIMITTEL)<br>8 February 2001 (2001-02-08)<br>see the whole document<br>-----                                                                                                                                                         | 1-24                  |
| A                                                    | J. K. SEYDEL ET AL: "Synthesis and<br>Quantitative Structure-Activity<br>Relationships of Anticonvulsant<br>2,3,6-Triaminopyridines"<br>J. MED. CHEM.,<br>vol. 37, no. 19, 1994, pages 3016-3022,<br>XP002286083<br>see compound 9, table I, page 3018<br>----- | 1-24                  |
| X                                                    | DATABASE BEILSTEIN<br>BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY,<br>FRANKFURT-MAIN, DE;<br>XP002286108<br>Database accession no. 6440745, 6442496 ,<br>6444607<br>abstract<br>& LITVINENKO, L ET AL: DOKL. CHEM 259,<br>1981, pages 317-320,<br>-----           | 1-3,5,6,<br>10,14,15  |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK2004/000162

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 18-24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK2004/000162

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| EP 1369420 A                              | 10-12-2003          | EP 1369420 A1              | 10-12-2003          |
|                                           |                     | WO 03104221 A1             | 18-12-2003          |
|                                           |                     | US 2004067980 A1           | 08-04-2004          |
| WO 0218318 A                              | 07-03-2002          | AU 3930701 A               | 13-03-2002          |
|                                           |                     | BR 0107154 A               | 18-06-2002          |
|                                           |                     | CA 2383855 A1              | 07-03-2002          |
|                                           |                     | WO 0218318 A1              | 07-03-2002          |
|                                           |                     | EP 1226107 A1              | 31-07-2002          |
|                                           |                     | JP 2004507517 T            | 11-03-2004          |
|                                           |                     | US 2002166181 A1           | 14-11-2002          |
| WO 0039118 A                              | 06-07-2000          | AU 2055500 A               | 31-07-2000          |
|                                           |                     | CA 2361149 A1              | 06-07-2000          |
|                                           |                     | EP 1140903 A1              | 10-10-2001          |
|                                           |                     | JP 2002533454 T            | 08-10-2002          |
|                                           |                     | WO 0039118 A1              | 06-07-2000          |
|                                           |                     | US 2004029874 A1           | 12-02-2004          |
|                                           |                     | US 6635657 B1              | 21-10-2003          |
| EP 0515684 A                              | 02-12-1992          | AU 7317391 A               | 03-09-1991          |
|                                           |                     | CA 2076012 A1              | 15-08-1991          |
|                                           |                     | EP 0515684 A1              | 02-12-1992          |
|                                           |                     | WO 9111994 A1              | 22-08-1991          |
|                                           |                     | ZA 9101101 A               | 27-11-1991          |
| EP 0386452 A                              | 12-09-1990          | DE 3903989 A1              | 20-09-1990          |
|                                           |                     | AT 94869 T                 | 15-10-1993          |
|                                           |                     | AT 143938 T                | 15-10-1996          |
|                                           |                     | AU 620206 B2               | 13-02-1992          |
|                                           |                     | AU 4926590 A               | 16-08-1990          |
|                                           |                     | CA 2008042 A1              | 10-08-1990          |
|                                           |                     | DE 59002783 D1             | 28-10-1993          |
|                                           |                     | DE 59010536 D1             | 14-11-1996          |
|                                           |                     | DK 386452 T3               | 25-10-1993          |
|                                           |                     | DK 553890 T3               | 18-11-1996          |
|                                           |                     | EP 0386452 A1              | 12-09-1990          |
|                                           |                     | EP 0553890 A1              | 04-08-1993          |
|                                           |                     | JP 2270835 A               | 05-11-1990          |
|                                           |                     | MX 9203496 A1              | 01-08-1992          |
|                                           |                     | US 5527945 A               | 18-06-1996          |
|                                           |                     | US 5656619 A               | 12-08-1997          |
|                                           |                     | US 5087743 A               | 11-02-1992          |
|                                           |                     | US 5225601 A               | 06-07-1993          |
|                                           |                     | US 5739374 A               | 14-04-1998          |
|                                           |                     | US 5248823 A               | 28-09-1993          |
|                                           |                     | ZA 9000963 A               | 30-10-1991          |
| WO 0109612 A                              | 08-02-2001          | US 6472165 B1              | 29-10-2002          |
|                                           |                     | AU 6278500 A               | 19-02-2001          |
|                                           |                     | CA 2380489 A1              | 08-02-2001          |
|                                           |                     | WO 0109612 A1              | 08-02-2001          |
|                                           |                     | EP 1200831 A1              | 02-05-2002          |
|                                           |                     | JP 2003506050 T            | 18-02-2003          |
|                                           |                     | TR 200200770 T2            | 21-03-2003          |